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Although there has been a decrease in age-corrected mortality due to 
coronary artery disease (CAD) since several decades, coronary heart death 
is still the major cause of death in Western societies (figure1) [1]. Despite 
this fall in mortality, due to treatment of acute events and primary and 
secondary prevention [2], the prevalence of CAD in the Western population 
is still very high [3]. Clinical manifestations of CAD include stable angina 
and the acute coronary syndromes (ACS), the latter can be classified after 
discharge and are divided in Non-ST Elevation Acute Coronary Syndrome 
(NSTE-ACS) and ST  Elevation Myocardial Infarction (STEMI). Treatment 
of CAD consists of lifestyle modification (e.g. diet, smoking cessation, 
physical activity), pharmacological treatment (e.g. beta-blockers, nitrates, 
statins, antiplatelet agents) and coronary revascularisation by either 






Figure 1: Cause of death in The Netherlands. 




Since the introduction of CABG in the 60s [4], surgical techniques have 
progressed, and care including pharmacotherapy during and after CABG 
has improved dramatically. The use of arterial grafts has resulted in better 
long-term patency of the grafts [5]. More recently, minimal invasive (‘off 
pump’) surgery has been introduced [6]. Also, percutaneous revascular-
isation has evolved after its introduction by Gruentzig in 1977 [7], 
particularly by the use of (drug-eluting) stents and medication during and 
after the PCI. Nowadays, both CABG and PCI are frequently used and 
widely accepted as effective modalities for the treatment of several clinical 
manifestations of CAD, with especially an increase in the number of PCIs in 
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The aims of treatment of patients with CAD are to improve prognosis by 
preventing myocardial infarction, heart failure, arrhythmias or death and to 
minimise or abolish (anginal) symptoms. Lifestyle modification is very 
important [9,10] and should be advised to all patients. Furthermore, 
intensive pharmacological treatment should be optimised in every patient 
with CAD. However, whether revascularisation by either CABG or PCI 
should be applied in the individual patient may be difficult to decide and 
depends of several patient characteristics and the extent of coronary 
abnormalities. Furthermore, in individual patients, treatment decisions 
should preferably be based on results of randomised trials and 
recommendations of guidelines.  
Limitations of randomised trials  
Randomised controlled clinical trials (RCTs) are the cornerstone of clinical 
evidence and recommendations of guidelines. However, it has been 
recognised that many of these trials have low external validity and that 
patients enrolled in these trials may not reflect those seen in daily clinical 
practice [11]. These trials have often only a limited follow-up period. 
Another limitation is that effects of treatment may be less clear in several 
specific subgroups, because they were not included in the trials (by 
exclusion criteria) or because only few patients in that subgroup were 
included. Results of registries or observational studies may be more 
externally valid than RCTs because patient inclusion is more complete. So, 
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treatment of the individual patient in routine daily practice should be based 
on results of both RCTs and observational studies [12].  
Sub-groups
Although randomised trials and observational studies may provide 
information on the treatment of the general patient, several patient 
characteristics may influence treatment decisions. Regarding coronary 
revascularisation, apart from comorbidities such as cerebrovascular 
disease, renal dysfunction and lung disease, particularly diabetes and the 
extent of coronary abnormalities are important. Diabetes has a high 
prevalence in patients with CAD. Furthermore, diabetic patients may have a 
different response to invasive treatment, and the combination of diabetes 
and coronary artery disease has often been associated with a poor 
prognosis. There is still debate whether patients with diabetes may profit 
more from CABG than PCI [13,14]. Particularly, because the introduction of 
newer interventional techniques like stenting has resulted in more 
favourable outcome in patients with diabetes [15]. 
For clinical decision-making, the extent of coronary artery disease is of 
course also of importance in choosing medical treatment, PCI or CABG. In 
the majority of patients with CAD, more than one coronary vessel is 
involved. Randomized trials comparing CABG with PCI for patients with 
multivessel disease (MVD) report similar long-term survival for CABG and 
PCI [15]. Observational studies, however, suggest survival benefit for 
CABG in these patients [16,17], although these analyses included patients 




by selection bias. Moreover, these studies give no insight whether 
completeness of revascularisation by PCI may improve prognosis. 
Scope of the thesis 
The main objective of the studies presented in this thesis is to give more 
insight in several aspects of coronary revascularisation, including decision- 
making in daily practice and (long-term) prognostic implications. Particular 
attention is paid to patients with diabetes and multivessel disease. 
Chapter 2 reviews current evidence of the prognostic implication of 
revascularisation in patients with non-ST elevation acute coronary 
syndrome. The results of both randomised trials and observational studies 
are summarised, mainly focussing on potential mortality reduction. Also, the 
various limitations of both randomised controlled trials and observational 
studies are discussed.  
The objective in Chapter 3 is to evaluate the potential association between 
completeness of revascularisation by percutaneous coronary intervention 
and the one-year occurrence of adverse events in patients with multivessel 
disease included in the Coronary Angioplasty versus Bypass 
Revascularisation Investigation (CABRI) trial. In Chapter 4, characteristics, 
treatment and outcome of patients with non-ST elevation acute coronary 
syndromes and multivessel coronary artery disease included in the Platelet 
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using
Integrelin Therapy (PURSUIT) are described. In Chapter 5, the long-term 
follow-up after invasive approach of coronary artery disease in daily 
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practice of patients included in the DUtch inventory of invasive Coronary 
Atherosclerosis Treatments (DUCAT) study is analysed. It concerns a two-
center follow-up study of all patients consecutively presented to the heart 
centers of Zwolle and Groningen during a 3-month period in 1992. In this 
study, patients with diabetes have been described in greater detail in  
Chapter 6. The Euro Heart Survey (EHS) program was developed to 
provide systematic information on the adherence to European and 
international guidelines in the member states of the European Society of 
Cardiology. In Chapter 7, treatment decisions regarding revascularisation 
in patients with stable coronary artery disease in patients enrolled in the 
Euro Heart Survey on Coronary Revascularisation (EHS-CR) are analysed. 
Chapter 8 presents the analysis of contemporary invasive management 
and prognosis of patients with diabetes and stable coronary artery disease 
enrolled in the Euro Heart Survey on Coronary Revascularisation (EHS-
CR). It concerns a systematic analysis of the relation between patient 
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CHAPTER 2
Coronary revascularisation for Non-ST 
Elevation Acute Coronary Syndrome 
í State of the art í
A. Breeman, J.P. Ottervanger 
E. Boersma, G. De Luca






Immediate as well as early revascularisation may be beneficial in patients 
with acute coronary syndromes (ACS) without ST elevation, but has 
traditionally employed as an ‘ischemia-guided’ strategy. A number of 
randomised trials (including more than 10,000 patients) and observational 
studies have compared routine invasive versus selective invasive treatment 
in patients with an acute coronary syndrome without ST elevation. Most 
randomised trials are limited by a high cross-over rate, whereas 
observational studies are limited by selection bias. Data from registries 
demonstrated benefits with an invasive approach. Results from randomised 
trials are less clear regarding mortality reduction, although long-term 
survival after hospital discharge may be better after the invasive approach. 
In the randomised trials there was a decreased risk of death or MI after the 
invasive approach (OR 0.88, 95% CI 0.76-1.0). Despite the optimal timing 
of angiography and subsequent revascularisation, if appropriate, may be 
uncertain, angiography and revascularisation should be considered in every 
patient admitted with an ACS without ST elevation, particularly in patients 
with high-risk characteristics, such as ST segment depression >0.1 mV, 
accelerated angina in the prior 2 months, nitrate use in the prior week 
before admission and elevated troponin. 
Introduction
Prognosis of patients with stable angina is in general very good, with an 
incidence of death or non-fatal myocardial infarction not exceeding 2% per 
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year [1]. In contrast, patients with an acute coronary syndrome (ACS) 
without ST elevation (NSTE-ACS) have a much worse prognosis, as 10-
15% experience death or non-fatal myocardial infarction within one year 
after admission [2]. According to the European and American treatment 
guidelines, and based on a large number of randomised trials, medical 
therapy of NSTE-ACS patients should preferably include heparin, 
antiplatelet agents and anti-ischemic agents [3]. Coronary revascularisation 
by either percutaneous coronary intervention (PCI) or coronary bypass 
surgery (CABG) is recommended in patients with recurrent ischemia, as 
well as in those who are otherwise at increased risk. In clinical practice, 
however, an important limiting factor to offer coronary revascularisation is 
its availability [4]. Patients presenting to hospitals without facilities for 
coronary revascularisation are much less likely to receive such treatment 
than those who present to hospitals with more extensive equipment. A 
number of registries and randomised trials describe potential benefits of 
(early) revascularisation in NSTE-ACS patients. We aimed to review these 
data.
Randomised trials 
Between 1994 and 2002 eight clinical trials were undertaken, which 
randomised approximately 9000 NSTE-ACS patients to an early invasive or 
conservative treatment strategy [5-11]. Recently, results of an additional 
trial (ICTUS) were published [12]. In most trials, patients randomised to 
invasive treatment underwent cardiac catheterisation during the first days 




was performed within 72 h), and, if necessary, revascularisation as soon as 
possible thereafter. Treatment decisions in patients randomised to the 
conservative treatment strategy were left to the discretion of the physician, 
and were mainly based on symptoms. All trials together, early invasive 
treatment was not associated with a mortality reduction after one-year 
follow-up (table 1; figure 1 left panel), although in a recently published 
meta-analysis it was shown that after hospital discharge the invasive 
approach is associated with mortality reduction after long-term follow-up 
[13]. Early invasive treatment was associated with a borderline statistically 
significant 12% relative reduction – and a 1.1% absolute reduction – in the 
composite endpoint of death or non-fatal myocardial infarction during long-
term follow-up compared with conservative treatment (8.7% versus 9.8% 
events; odds ratio 0.88 and 95% CI 0.77-1.0). However, there was 
evidence of a differential treatment effect between the separate trials.  
Figure 1: Mortality (left panel) and the composite endpoint of death or non-fatal MI 
(right panel) in the randomised trials comparing invasive with conservative 
approach for non-ST elevation ACS. 

































































































Particularly, divergent results were observed in the VANQWISH trial, as 
patients randomised to early invasive treatment had significant higher 1-
year event rates (22.1% versus 14.2% events; odds ratio 1.7 and 95% CI 
1.2-2.4) [6]. The VANQWISH results, however, have been challenged, 
since a relative large proportion of patients allocated to the conservative 
strategy actually underwent coronary revascularisation within 30 days after 
randomisation (33% compared with 44% in the early invasive arm). 
Furthermore, in the earlier trials, among which VANQWISH, neither 
intracoronary stents nor GP IIb/IIIa inhibitors were available for patients 
undergoing PCI. Finally, in VANQWISH an exceptionally high peri-operative 
mortality was observed in the invasive arm (11.6% versus 3.4% events; 
odds ratio 3.7 and 95% CI 1.0-13.6). A meta-analysis of the five recent 
trials revealed a 28% relative reduction – and a 2.5% absolute reduction – 
in the composite endpoint of death or non-fatal myocardial infarction by the 
early invasive strategy (7.0% versus 9.5% events; odds ratio 0.72 and 95% 
CI 0.60-0.86). 
In ICTUS, a total of 1201 NSTE-ACS patients who had a cTnT 
concentration >0.03 μg/L at presentation, were randomly assigned to a 
treatment strategy that aimed at coronary angiography and subsequent 
revascularisation within 24-48 hrs (early invasive approach) or to a 
treatment strategy in which coronary angiography (and revascularisation) 
was only performed in cases of refractory angina or ischemia on 
predischarge exercise testing (selective invasive approach). In both 
treatment arms abciximab was given whenever a PCI was performed, 
whereas coronary stents were used liberally. Within one year after 
randomisation, coronary revascularisation was performed in 73% of 
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patients allocated to early invasive treatment versus 47% in those allocated 
to selective invasive treatment, whereas timing of revascularisation was 
within 30 days in almost all patients who had revascularisation. The early 
invasive approach was associated with an increased incidence of non-fatal 
myocardial infarction during one-year follow-up compared to the selective 
invasive approach (15% versus 10%; odds ratio 1.5 and 95% CI 1.1 – 2.0), 
but most events were related to the revascularisation. Patients allocated to 
the invasive approach had a lower incidence of rehospitalisation for ACS 
within one year (7.4% and 10.9%; odds ratio 0.68, 95% CI 0.47-0.98).There 
was no difference in all-cause mortality after one year between the 
separated approaches (2.5% versus 2.5%; odds ratio 0.99 and 95% CI 
0.49-2.00). Compared to the other randomised trials, patients allocated to 
conservative treatment had a high frequency of cross-over to (early) 
revascularisation (47%) and a low one-year mortality (2.5% in ICTUS vs. 
4.4% in the other trials). 
Apart from potential effects on mortality and recurrent MI, in the 
randomised trials it was shown that early revascularisation may particularly 
reduce anginal complaints and rehospitalisation [13]. Also in ICTUS, the 
incidence of rehospitalisation for anginal complaints was significantly lower 
in those allocated to the early invasive strategy. 
Randomised controlled trials are the cornerstone of evidence based 
medicine. Still, clinical trials comparing invasive versus medical approach in 
NSTEMI should be interpreted with caution. Importantly, in these trials, 
many patients allocated to conservative treatment crossed-over to invasive 
treatment, whereas many patients allocated to invasive treatment did not 




a selected patient group, with differences to patients seen in daily clinical 
practice. Also, these trials cannot be blinded to treatment allocation. These 
factors may have caused bias, and particularly cross-over in the 
conservative group may have contributed to an underestimation of the 
benefits with an invasive approach in NSTE-ACS. 
Observational studies 
Apart from the randomised trials, there are several observational studies, 
including registries, regarding the potential benefit of revascularisation in 
patients with ACS without ST elevation [14-19]. In the OASIS registry, 
evaluating approximately 8000 patients with suspected NSTE-ACS from 6 
countries, a reduction in refractory ischemia and need for hospitalisation 
was observed after revascularisation, but not a decrease of mortality [16]. 
Analyses of data from patients included in GUSTO IV-ACS provided 
evidence that coronary revascularisation within 30 days after admission 
was associated with a favourable one-year survival, with one-year mortality 
2.3% in the invasive group vs 5.6% in the conservative group [17]. This 
beneficial effect of revascularisation was also observed after adjusting for 
several baseline characteristics and a propensity score: patients with 
revascularisation had a relative risk of one-year mortality of 0.53 (95% CI 
0.37-0.77) compared to patients without revascularisation. Moreover, in this 
analysis, survival benefit after revascularisation, independent of early risk 
stratification, was consistently shown in every subgroup studied. 
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The CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients 
Suppress Adverse Outcomes With Early Implementation of the ACC/AHA 
Guidelines) Quality Improvement Initiative evaluated care patterns and 
outcomes of 17,926 high-risk NSTE ACS patients with positive cardiac 
markers and/or ischemic electrocardiographic changes at admission [18]. 
Patients treated with early invasive management had a lower risk of in-
hospital mortality after adjusting for differences in clinical characteristics 
and after comparing propensity-matched pairs (2.5% vs 3.7%, P<0.001, 
odds ratio 0.67; 95% CI 0.56-0.80).  
In summary, in most observational studies benefits of early 
revascularisation appeared larger than in the randomised trials, even after 
adjustment for several patient and hospital characteristics. It should be 
appreciated, nevertheless, that such multivariable adjustments may not 
correct for all patient characteristics, and does not fully compensate the 
effect of careful selection of patients who are candidates for 
revascularisation, and those who are not. The true benefit of 
revascularisation might probably be overestimated by registries and 
underestimated by randomised trials. 
Revascularisation in practice 
Recent European and American guidelines for clinical practice advise an 
invasive strategy in patients with ACS and failed medical therapy as well in 
high risk patients [3,20]. This is in agreement with observations from FRISC 
II and TACTICS-TIMI 18 demonstrating that the absolute reduction of death 




medical therapy include ST segment depression >0.1 mV, accelerated 
angina in the prior 2 months, nitrate use in the prior week before admission 
and elevated troponin [21]. Whether other diagnostic tools, such as 
(contrast) echocardiography may be helpful in selecting patients for an 
early invasive approach should be assessed [22,23]. Finally, although a 
number of studies suggest benefits of revascularisation, data from 
registries showed that in daily clinical practice an early invasive 
management strategy is commonly denied in many high-risk patients with 
NST-ACS [18,24-25].
Timing of revascularisation 
The hazard of an unfavourable event in patients with NST-ACS is highest 
within the first 48 hours after admission [26]. Nevertheless, the appropriate 
timing of coronary angiography and revascularisation remains 
controversial. In an early invasive approach, the risk of peri-procedural 
complications may be increased [27]. Therefore, a period of ‘cooling off’, in 
which patients are medically stabilised, has been recommended. This 
allows partial resolution of the initially strong inflammatory response with 
liberation of cytokines [28], increased generation of free radicals [29], and 
enhanced activity of the coagulation system [30]. On the other hand, early 
angiography and subsequent revascularisation may prevent myocardial 
infarction or death in a high risk period, particularly with the use of stents 
and GP IIb/IIIa inhibitors. In PURSUIT, early PCI (within 24 h) in patients 
receiving a GP IIb/IIIa inhibitor had the lowest event rate after 30 days [31]. 
In TACTICS TIMI 18, there was no mortality difference between patients 
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with revascularisation within 48 hours after randomisation, and those with 
revascularisation after 48 hours [32]. In GUSTO IV-ACS, an increased 
mortality was found in patients with early CABG [17]. Possibly, when 
indicated, PCI should be performed, as soon as possible after admission 
for ACS while CABG should be deferred. However, until now, there are only 
few randomised data available, comparing an early with a later invasive 
approach, showing conflicting results [33,34]. 
Angioplasty or surgery 
In the randomised trials of invasive versus conservative management in 
ACS, there are different findings with regard to mortality after CABG. In 
FRISC II the in-hospital and 30-day mortality after CABG in the invasive 
group was respectively 1.2% and 2.1%. Similar low rates were observed in 
TACTICS TIMI 18, and outcome was comparable between patients 
undergoing CABG and PCI. In VANQWISH, however, there was a very 
high mortality in the CABG group. In recent randomised trials comparing 
stented angioplasty and bypass surgery, which included patients with non-
STEMI, the incidence of death or myocardial infarction during follow-up of 2 
years were similar between the two groups [35,36]. The less favourable 
outcome after CABG in GUSTO IV-ACS was most likely related to the 
selection of patients with more extensive disease to undergo surgery. Data 
of randomised studies with drug-eluting stents are not yet available. 
Whether complete revascularisation may reduce mortality compared to 




mortality difference, but a trend to fewer readmissions for unstable angina 
and less long-term antianginal medication [37]. 
GP IIb/IIIa inhibitors 
A number of previous studies have demonstrated beneficial effects of GP 
IIb/IIIa inhibitors in patients with ACS without ST elevation, in particular in 
patients undergoing PCI [38-41]. In the guidelines of management of 
patients with non-STEMI, use of GP IIb/IIIa inhibitors are recommended, in 
addition to standard treatment (aspirin and unfractionated heparin or low-
molecular-weight heparins) for patients with high-risk features such as 
elevated troponin, ST-segment changes, or recurrent ischaemia [3,42]. GP 
IIb/IIIa inhibitors are particularly effective in patients with NSTE-ACS when 
early PCI is performed [31]. GUSTO IV-ACS did not show beneficial effects 
of abciximab [17]. However, in this trial, coronary angiography was 
discouraged within 60 h after randomisation unless the patient had 
recurrent or continuing ischemia at rest associated with ischemic ST-T 
changes that were unresponsive to intensive medical therapy. Indeed, only 
128 patients (1.6%) had PCI during study drug infusion. 
In summary, in patients with non-ST-segment elevation ACS and early 
invasive management, optimal pharmacological therapy should be 
supported, including GP IIb/IIIa antagonists [43]. However, in women and 
troponin-negative patients data are less clear and enhanced risk 
stratification is needed in these subgroups [44]. Furthermore, all previous 
large trials on GP IIb/IIIa inhibitors during PCI for non-ST ACS have been 
performed without routine use of clopidogrel. A relative small study was 
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recently published, and suggested no benefit of routine GP IIb/IIIa inhibitors 
compared to provisional use in patients with non-ST ACS treated with 
aspirin, heparin and clopidogrel [45]. 
Sub-groups of patients 
There are several patient characteristics that should be considered in 
patient selection for revascularisation. Although increasing age is an 
important risk factor for adverse outcome among patients with acute 
coronary syndromes, elderly patients are more often managed 
conservatively. A sub-analysis of patients of the TACTICS-TIMI 18 trial 
showed that, despite an increased risk for major bleeding in patients older 
than 75 years of age, a routine early invasive strategy can significantly 
improve ischemic outcomes in elderly patients with unstable angina and 
non-ST segment elevation MI [46]. These data have been confirmed in 
other studies [47,48].  
In patients admitted with NSTE-ACS, females are often older and have 
more often diabetes mellitus or hypertension [49-51]. It has been suggested 
that GP IIb/IIIa inhibitors are not beneficial in females with unstable angina 
[52] and that invasive treatment is less effective in females compared to 
males [53,54]. This was, however, not confirmed by other studies [55]. Also 
data from GUSTO IV-ACS did not show significant differences between 
males and females regarding mortality reduction of revascularisation [17]. 
In most studies, diabetic patients admitted with a non-ST elevation ACS are 




more previous cardiovascular events, including MI, congestive heart failure, 
stroke, and revascularisation procedures [56]. Furthermore, diabetes is an 
independent predictor of mortality after a non-ST elevation ACS [56-58]. 
Coronary revascularisation in patients with diabetes and non-ST elevation 
ACS may be, however, as effective as in patients without diabetes [59]. 
Conclusions 
Although the results observed in randomised trials are less clear than 
observational studies, we believe that angiography and revascularisation 
should be strongly considered during the initial hospitalisation in high-risk 
patients with NSTE-ACS and in case of failure of medical therapy in 
suppressing ischemia. The optimal timing of angiography and subsequent 
revascularisation if appropriate remains uncertain, but possibly PCI should 
be performed as soon as possible after admission for ACS, while CABG 
should be deferred. We did not review data on benefits of revascularisation 
apart from survival or recurrent MI, but patients have probably less com-
plaints during follow-up after revascularisation, as was shown in RITA 3. 
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 percutaneous coronary intervention 
A. Breeman, E. Boersma, M.J. van den Brand, 
L. van Herwerden, P.W. Serruys 
for the CABRI-investigators 






Objective: To evaluate the relationship between the completeness of 
revascularisation by percutaneous coronary intervention and the one-year 
occurrence of adverse cardiac events in patients with multivessel disease. 
Patients. Patients with stable or unstable angina pectoris, or with exercise-
induced ischaemia, were enrolled in the Coronary Angioplastry versus 
Bypass Revascularisation Investigation (CABRI). 
Methods: In CABRI, patients were randomised to coronary bypass grafting 
(CABG; n=513) or angioplasty (PTCA; n=541). Revascularisation in 
patients randomised to PTCA was defined as complete if no lesions with a 
diameter stenosis <50% remained post-procedure. Patients with complete 
revascularisation were distinguished from those with one, two or three or 
more remaining lesions, respectively. Differences in baseline 
characteristics and in the one-year occurrence of death, myocardial 
infarction, (re)CABG and (re)PTCA between these subgroups were 
evaluated. Comparisons were made with patients randomised to CABG. 
Results: Complete revascularisation was obtained in 148 patients 
randomised to PTCA (27%). In 147 (27%) cases one lesion remained, 
while there were 122 (23%) and 119 (22%) patients with two and three or 
more remaining lesions, respectively. Five (1%) patients could not be 
classified. The one-year rates of either death or MI were 9.5%, 5.4%, 8.2% 
and 12.6% in the respective PTCA subgroups (p=0.225), and 6.2% in 
patients randomised to CABG (comparison with three or more remaining 
lesions after PTCA: p=0.017) The percentages of repeat interventions 
during one-year follow-up were 29.7%, 29.3%, 39.3% and 51.3% 
(p<0.001), much higher than after CABG (3.5%; p<0.001). 
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Conclusion: Complete revascularisation by PTCA in multivessel coronary 
disease did not result in a lower death or MI rate compared with incomplete 
revascularisation. Overall the patient’s prognosis after PTCA is similar to 
CABG, but patients with three or more remaining lesions after PTCA had a 
worse prognosis than CABG patients. 
Introduction
To date, percutaneous coronary interventions have a wide indication. 
Whereas some years ago coronary bypass surgery was the dominant 
therapeutic option in patients with multivessel coronary disease, due to 
gained experience and the availability of sophisticated devices as 
intracoronary stents, nowadays most of these patients  are also eligible for 
percutaneous treatment. Randomised clinical trials indicate that, at least in 
the medium term, both revascularisation strategies are equally effective in 
terms of mortality and the occurrence of myocardial infarction [1,2].  The re-
intervention rate, however, appears to be much higher after angioplasty, 
especially during the first year. This can partly be explained by the 
restenosis process. Another aspect is that complete revascularisation can 
be difficult to realise by percutaneous intervention, especially in patients 
with complex lesions. Therefore, interventional cardiologists regularly opt 
for the strategy of incomplete revascularisation to relieve cardiac 
symptoms. Recent reports indicated that this latter strategy is as safe and 
effective as the strategy of complete revascularisation by percutaneous 
treatment [3,7]. So far, however, no comparison has been made with 




relationship between the degree of (in)completeness and the occurrence of 
adverse events. The current paper concentrates on these two aspects, and 
presents data from the Coronary Angioplasty versus Bypass 
Revascularisation Investigation (CABRI) with respect to the completeness 
of the revascularisation after coronary intervention and the occurrence of 
cardiac complications at one-year follow-up. 
Methods
Coronary Angioplasty versus Bypass Revascularisation Investigation 
(CABRI)
CABRI is a multicentre, randomised trial comparing the strategies of 
revascularisation by percutaneous transluminal coronary balloon 
angioplasty (PTCA) and coronary artery bypass grafting (CABG) in patients 
with multivessel coronary disease [8]. Included were patients <75 years of 
age with a diameter stenosis (DS) <50% in at least two main epicardial or 
large side branches as viewed online in two projections on the baseline 
angiogram. At least one of the lesions had to be amenable to PTCA. 
Patients with either stable or unstable angina pectoris were eligible, as well 
as a-symptomatic patients who exhibited unequivocal ischaemia during 
exercise testing. Excluded were patients with left main disease, overt 
cardiac failure, those with a recent myocardial infarction (MI) or a recent 
cerebrovascular accident, and patients with a previous PTCA or CABG. 
The primary endpoint in CABRI was mortality and anginal status at one-
year follow-up. Secondary endpoints were MI and the need for repeat 
revascularisation. CABRI was conducted in the first half of the 1990s, an 
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era in which neither stents nor glycoprotein IIb/IIIa inhibitors were available 
in clinical practice. 
Completeness of revascularisation 
The location of lesions in the coronary tree is described according to the 
American Heart Association 15-segment system (figure1) In patients 
allocated to PTCA, an initial strategy of partial revascularisation was 
allowed, i.e. not all significant lesions had to be attempted. Consequently, 
for each lesion three possible situations could appear: no attempt was 
made to dilate the lesion, a successful attempt was made, or an 
unsuccessful attempt was made. A lesion was defined to be successfully 
dilated if the post-procedural DS was less than 50%, as viewed online in 
Figure 1: Schematic view of the coronary tree according to the American Heart 
Association 15-segments system. 1=proximal RCA; 2=mid RCA; 3=distal RCA; 
4=postierior descending from dominant RCA; 5=left main stem; 6=proximal LAD 
(proximal to first septal); 7=mid LAD (distal to the first diagronal); 8=distal LAD (distal to 
the first diagonal); 9=first diagonal of LAD; 10=second diagonal of LAD; 11=main 
circumflex; 12=obtuse marginal (lateral) cirumflex; 13=mid circumflex; 14=posterolateral 




two angiographic projections. Revascularisation by percutaneous treatment 
was defined as complete if all lesions were successfully dilated – i.e. if 
there were no remaining lesions with DS <50% í and incomplete 
otherwise. A degree of (in)completeness was distinguished on the basis of 
the number of remaining lesions. Surgery was viewed as the gold standard 
for restoration of the coronary perfusion. Therefore, patients randomised to 
PTCA who crossed to CABG (i.e. who underwent cardiac surgery before or 
instead of a percutaneous intervention) were classified as completely 
revascularised.
Data analysis 
Patients randomised to PTCA were divided into separate groups according 
to the completeness of the initial procedure. Patients who ultimately had a 
complete revascularisation were distinguished from those with one, two, 
and three or more remaining lesions, respectively. Differences in baseline 
characteristics between these subgroups were evaluated by uncorrected 
ȋ2-square test (dichotomous variables) ore one-way analyses of variance 
(continuous variables), with statistical significance at the conventional 
p=0.05 level. 
The occurrence of major adverse cardiac events [death, MI, (re)CABG, and 
(re)PTCA] during one-year follow-up is presented as a percentage. 
Differences in event rates between patients randomised to CABG on the 
one hand, and those randomised to PTCA with no or three or more 
remaining lesions on the other hand, were evaluated by a series of two 
uncorrected ȋ2-square tests. To prevent increasing type I error, significance 
of these tests was stated at p=0.025. Furthermore, within the group of 
patients randomised to PTCA, the relation between the completeness of 
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revascularisation and the occurrence of adverse events was studied by 
means of Mantel-Haenszel ȋ2-square tests (significance at p=0.05). 
Results
Angiographical success rates 
In CABRI, 513 patients were randomised to CABG and 541 to PTCA. 
Fifteen patients randomised to PTCA crossed to CABG, and the baseline 
coronary angiogram was lacking in five additional patients. Thus there were 
521 PTCA patients who were treated as randomised with complete pre- 
and post-procedural angiographic information. Among these patients, 1856 
significant lesions were reported on the baseline angiogram, implying an 
average of 3.6 lesions per patient. There were 314 total occlusions (17% of 
all lesions). A stenosis in the proximal part of the LAD was observed in 233 
(13%) cases. An attempt to dilate a lesion was made in 66% of the non-
total occlusions (figure 2) and in only 39% of the total occlusions (p<0.001; 
figure 3). The proximal LAD was more often attempted than the other 
lesions (79% vs. 64%, p<0.001 in non-total occlusions and 57% vs. 38%, 
p=0.121 in total occlusions). In the non-occluding lesions, 93% of the 
attempts were successful. Although this percentage was significantly lower 
in the total occlusions (p<0.001), 72% of the attempts in the latter lesions 




Figure 2: Number of lesions in patients randomised to PTCA with a pre-
procedural diameter stenosis >50% and <100%. The location of the lesions is 
indicated by the segment number according to the American Heart Association 
15-segments system (see figure 1). The white, black and grey part of the bars 
indicate lesions that were attempted with success, attempted without success, 
and not attempted at all, respectively. 
Figure 3: Number of lesions in patients randomised to PTCA with a pre-
procedural diameter stenosis of 100% (total occlusion). For legends see figure 2.  
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Table 1: Baseline characteristics 
   
Allocated strategy CABG PTCA




0 1 2 t3 (p-value)
Number of patients 513 148 147 122 119  
    
Demographics and clinical presentation
Median age  













Male gender (%) 78 76 84 68 81 0.018 
Median LVEF  













      
Angina (CCS classification)
No angina or class I/ class II 
or III/ class IV or unstable 
angina (%) 
11/60/29 13/62/25 13/65/22 8/62/30 13/63/24 0.716 
      
Function (NYHA classification)
Class 0 or I/ class II/ class 
III or IV (%) 
75/20/5 90/9/1 78/19/3 73/25/4 71/21/8 0.006 
      
History 
Infarction (%) 42 40 42 33 53 0.020 
Periph vessel disease (%) 6 6 4 8 11 0.188 
CVA (%) 5 6 4 4 11 0.061 
Smoking (%) 55 57 67 52 54 0.061 
Diabetes mellitus (%) 12 9 9 14 17 0.142 
Hypertension (%) 37 32 31 38 40 0.479 
Medication
Beta-blockers (%) 65 67 64 61 50 0.091 
Calcium antagonists (%) 65 65 66 69 71 0.784 
Nitrates (%) 70 62 64 68 66 0.875 
     
Lesion characteristics 
Number – 2/3/ 










     
Median (average) number - 3 (2.7) 3 (3.1) 4 (3.8) 5 (5.0) <0.001 
Bifurcation (%) - 10 9 7 7 0.875 
Eccentric (%) - 54 44 42 42 0.208 
Long (%) - 73 83 80 96 <0.001 
Tandem (%) - 12 7 4 8 0.207 
Total occlusion (%) - 7 20 18 27 <0.001 
Thrombus (%) - 3 1 2 4 0.391 




Completeness of revascularisation in patients randomised  to PTCA  
The initial intervention resulted in a complete revascularisation in 148 of the 
patients randomised to PTCA (27%; 133 patient who were treated as 
randomised plus 15 who crossed to CABG). In another 147 (27%) cases 
there was only one remaining lesion, while there were 122 (23%) and 119 
(22%) patients with two and three or more remaining lesions, respectively. 
The five (1%) patients with a missing baseline angiogram could not be 
classified. Table I presents the baseline characteristics of these groups. 
There were some statistically significant differences in patient 
demographics (gender), clinical presentation (NYHA class), and history 
(previous infarction) between the four groups. Furthermore a significant 
relationship was observed between the number of lesions at presentation 
and the number of remaining lesions: e.g. 49% of patients with complete 
revascularisation had two lesions at baseline, while this percentage was 
only 4% among those with two remaining lesions. Also the length and 
severity (total occlusion) of the lesion were significantly related to the 
degree of completeness of revascularisation in patients randomised to 
PTCA. On the other hand, the percentage occurrence of otherwise more 
complex lesions (e.g. eccentric lesions, lesions with thrombus formation, 
calcified lesions) was similar among the four groups. 
Major adverse cardiac events 
Table 2 presents the occurrence of cardiac complications in CABRI in 
relation to the completeness of revascularisation. Follow-up information 
was complete in all but four patients. Among the patients randomised to 
PTCA, both short-term (up to 30 days after the initial procedure) and long-
term mortality was lowest in those with one remaining lesion after the initial 
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procedure (0.7% and 2.0%, respectively). Mortality was relatively high in 
patients with complete revascularisation (2.1% at short term and 5.4% at 
long-term follow-up) and in those with three or more remaining lesions 
(2.5% and 5.0%). There was no significant relationship between the degree 
of completeness of revascularisation and mortality, neither so if the group 
of patients with no remaining lesions was ignored. The percentage 
occurrence of MI (and the occurrence of either death or MI) showed a 
similar pattern: lowest events rates in patients with one remaining lesion, 
highest rates in those with no and three or more remaining lesions, and no 
significant relation between the degree of completeness and short-term and 
long-term event rates. The observed differences in mortality rates between  
CABG and  the PTCA sub-groups with no and three or more remaining 
lesions were not statistically significant. The combined rate of death or MI 
at one-year follow-up, however, was significantly higher in PTCA patients 
with three or more remaining lesions than in those randomised to CABG 
(12.6% vs. 6.2%; p=0.017). 
The rate of subsequent coronary bypass operations among patients 
randomised to PTCA was related to the degree of (in)completeness of the 
initial procedure. During the first 30 days after this procedure, 2.8% of 
patients with no remaining lesions underwent a CABG versus 20.2% of 
those with three or more remaining lesions (p<0.001).  At one-year follow-
up these percentages were 7.4% and 37.0% (p<0.001) respectively. In 
contrast, the percentage occurrence of re-PTCA was similar among the 
PTCA subgroups. 
An interesting aspect is the difference in timing of repeat procedures 
between the distinct subgroups. In patients with three or more remaining 




performed within 30 days of the initial procedure. These percentages were 
apparently lower in those with two and one remaining lesion: 41% and 15% 
of the CABGs (and 33% and 14% of the repeat interventions) were done 
within one month. In patients with a complete revascularisation, 38% of the 
CABGs  (and 24% of the repeat interventions) were performed during the 
first month. 
Discussion 
Patients with multivessel coronary disease usually benefit from invasive 
treatment strategies that aim at revascularisation of the coronary system: 
coronary surgery or percutaneous intervention. To relieve patients’ 
complaints and restore myocardial perfusion it would seem logical to try to 
achieve a complete revascularisation. However, several investigations have 
demonstrated that a strategy of incomplete revascularisation is as safe (no 
excess death or MI rate) and effective (pain relief) as complete 
revascularisation [3-7]. 
The presented data confirm these conclusions to a large extent, although 
some remarks need to be made. 
Completeness of revascularisation and life threatening events 
Among the PTCA patients who were treated as randomised, approximately 
seven out of each ten non-occluding lesions were attempted with a success 
rate of over 90%. Total occlusions were less frequently attempted, with a 
lower, but still high rate of success. These data affirm other observations in 
the pre-stent era [4]. A complete revascularisation was only realised in one 
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quarter of the patients, similar to findings in a registry of consecutive 
patients with multivessel disease who underwent a PTCA in the same 
period (17%) [3], and with results from the Multivessel Angioplasty 
Prognosis Study (MAPS) [9]. 
The subdivision of patients randomised to PTCA according to the 
completeness of the initial revascularisation procedure was not prespecified 
by the protocol, and results of analyses on these subgroups should 
therefore be interpreted with caution. Differences in event rates between 
the PTCA subgroups might be biased by known or unknown differences in 
baseline clinical and angiographical characteristics. Indeed, differences 
were observed with respect to medical history and to the number and 
severity of lesions to be treated. From a formal statistical point of view the 
current data did not show a relation between the rate of death or 
myocardial infarction during one-year follow-up and the degree of 
completeness of revascularisation by PTCA. It is true that the percentage 
occurrence of life-threatening complications moved upwards in patients 
with one, two, and three or more remaining lesions, respectively, but event 
rates were also high among patients with no remaining lesions. On the 
other hand, PTCA patients with three or more remaining lesions had a 
doubled risk of death or MI within the first year after the procedure 
compared with bypass surgery. 
Furthermore, the possibility of type II errors should not be ignored, as the 
number of patients in each subgroup was relatively small. Finally, it cannot 
be excluded that the relatively high event rate in patients with complete 






Patients with remaining significant lesions after percutaneous intervention 
most likely suffer from severe and diffuse coronary artery disease, and an 
early bypass operation is therefore warranted. Indeed, the need for repeat 
interventions to prevent life-threatening thrombotic events has been largely 
recognised, as the percentage of CABG increased steeply with increasing 
incompleteness of revascularisation by PTCA. 
Patients with incomplete revascularisation not only underwent a repeat 
intervention more often, but also much earlier than those with a more 
complete revascularisation. Patients without remaining lesions formed an 
exception: 38% of CABGs during follow-up were performed in the first 
month. This observation might again be explained by a relatively high 
percentage of ‘bail out’ situations after the PTCA procedure in this group of 
patients, and leads as a matter of course to the most important limitation of 
our investigation: CABRI was conducted in the pre-stent era. As the 
immediate outcome of percutaneous treatment can be improved by 
coronary stenting [10,11], the percentage of patients with a complete and 
more stable result after percutaneous coronary intervention in today’s 
clinical practice will likely be higher than in our population. Indeed, in the 
Arterial Revascularisation Therapies Study (ARTS: a randomised 
comparison of bypass surgery and coronary stenting in multivessel 
coronary patients), 73% of the stent procedures resulted in a complete 
revascularisation [12], which is considerably higher than the 27% obtained 
after balloon angioplasty in our dataset. The favourable angiographic result 
by coronary stenting, however, did not result in a improved outcome, as the 
one-month death and MI rates in the angioplasty arms of CABRI and ARTS 
were similar [12]. Hence, our data of the pre-stent era regarding the relation 
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between the completeness of revascularisation by percutaneous treatment 
and patient’s prognosis are still valuable. 
Percutaneous intervention of bypass surgery? 
The strategy of complete revascularisation by PTCA in patients with 
multivessel coronary artery disease did not result in a lower death or MI 
rate during one-year follow-up as compared with a strategy of incomplete 
revascularisation. Thus, complete revascularisation by percutaneous 
intervention does not seem sensible in all patients. This is supported by the 
observation that patients with one remaining lesion after PTCA had a lower 
rate of life-threatening events than patients who initially underwent cardiac 
surgery, be it at the cost of a higher re-intervention rate. Additional 
analyses among patients with the worst angiographical result in patients 
with multivessel coronary artery disease, coronary bypass surgery and 
percutaneous intervention should not be played off against each other, but 
should be considered as complementary parts of an umbrella coronary 
revascularisation strategy. Treatment should be tailored to the individual 
patient’s situation, taking into account the pros and cons of both strategies. 
These considerations should also include cost aspects. In contrast to the 
ARTS trial, however, CABRI was not designed to study cost-effectiveness 
relations between percutaneous interventions and surgery. Future analyses 
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CHAPTER 4
Characteristics, treatment and outcome 
 of patients with non-ST-elevation acute 
 coronary syndromes and multivessel
coronary artery disease: observations
from PURSUIT 
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Background: The 6-month clinical outcome of patients with multivessel 
disease enrolled in PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable 
Angina: Receptor Suppression Using Integrilin Therapy) is described. 
Patients with complete angiography data were included; multivessel 
disease was stratified according to the treatment strategy applied early 
during hospitalization, i.e. medical treatment, percutaneous coronary 
intervention (PCI) (balloon), PCI (stent), or coronary artery bypass grafting 
(CABG).
Methods: Patients were divided into three groups according to the 
treatment strategy applied during the first 30 days of enrolment. Patients 
who did not undergo a percutaneous or surgical coronary intervention were 
classified as medically treated. Patients who underwent a PCI (prior to a 
possible CABG) were separated from those who underwent a CABG (prior 
to a possible PCI). The PCI group was further subdivided: patients 
receiving 1 coronary stents were separated from those in whom no stents 
were used.
Results: The mortality rate at 30 days was 6.7, 3.9, 2.4 and 4.8% for the 
medical treatment, PCI (balloon), PCI (stent) and CABG groups, 
respectively (p value = 0.002). Differences as observed at 30 days were still 
present at 6-month follow-up with 11.1, 5.8, 5.5 and 6.5% mortality event 
rates for the aforementioned groups (p value = 0.002). The 30-day 
myocardial infarction (MI) rate according to the opinion of the Clinical 
Events Committee was lower among medically than non-medically treated 
patients, with the highest event rate observed in the CABG group (27.7%). 
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Approximately half of the MIs in the PCI and CABG subgroups occurred 
within 48 h after the procedure.  
Conclusions: The observed differences in clinical outcomes are explained 
by an imbalance in baseline characteristics and comorbid conditions 
between the analyzed groups of patients. 
Introduction
Several clinical trials have been performed to evaluate whether patients 
with coronary artery disease benefit most from medical treatment only, 
percutaneous coronary intervention (PCI), or coronary bypass surgery 
(CABG) [1,2]. Other studies have specifically compared percutaneous 
transluminal coronary balloon angioplasty (PTCA) against CABG [3–9] and 
finally contemporary trials of coronary stenting and optimal adjunctive 
pharmacological therapy versus CABG have recently been reported [10–
12]. However, most of these studies have predominantly included patients 
with chronic stable angina and few data are available on the characteristics 
and clinical outcome of patients with multivessel disease presenting with an 
acute coronary syndrome. 
The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression 
Using Integrilin Therapy (PURSUIT) trial was a large-scale randomized 
clinical trial on the effects of eptifibatide versus placebo in patients with 
acute coronary syndromes without persistent ST elevation [13]. As the 
enrolment criteria were broad, PURSUIT encompasses a wide variety of 
patients, hospital settings and treatment policies, and therefore accurately 




The aim of this study was to describe the characteristics and short-term 
clinical outcome of patients with multivessel coronary artery disease in the 
PURSUIT population according to the treatment strategy applied early 
during hospitalization. 
Materials and Methods 
Patient population 
The design and methods of the PURSUIT trial have been previously 
published [13]. In summary, patients were eligible if they presented within 
24 h of an episode of ischemic chest pain (>10 min), and had either 
transient ST elevation (>0.5 mm), transient or persistent ST depression (0.5 
mm), T wave inversion (>0.1 mm), or elevation of the creatine kinase MB 
fraction (CK-MB) above the upper limit of normal (ULN). Patients with 
persistent (>30 min) ST elevation were excluded. Eligible patients were 
randomly assigned to treatment with eptifibatide or placebo. All other 
treatment decisions, including the use and timing of PCI or CABG were left 
at the discretion of the treating physician. 
Coronary angiography was performed within 30 days of enrolment in 5,937 
(63%) of the 9,461 patients who participated in PURSUIT (figure 1). Among 
patients with complete angiographic data, 3,067 (58%) had a significant 
stenosis (>50% diameter stenosis by visual inspection) in 2 major native 
coronary arteries or in the left main stem. These patients were classified as 
having multivessel coronary artery disease and are the subjects of interest 
for the current analysis. 
Multivessel disease in NSTE-ACS 
___________________________________________________________________ 
54
Classification according to applied treatment strategy 
Patients were divided into three groups according to the applied treatment 
strategy during the first 30 days of enrolment. Patients who did not undergo 
a percutaneous or surgical coronary intervention were classified as 
medically treated. Patients who underwent a PCI (prior to a possible 
CABG) were separated from those who underwent a CABG (prior to a 
possible PCI). The PCI group was further subdivided: patients receiving 1
Figure 1: PURSUIT patient population flow chart stratified accoording tot the 
number of diseased vessels and treatment strategy applied to patients with 




coronary stents were separated from those in whom no stents were used 
(figure 1). 
Definition of myocardial infarction 
The primary endpoint of PURSUIT was a composite of death or non-fatal 
myocardial infarction (MI) at 30 days. A computerized algorithm was used 
to review the clinical events. If a possible event was identified, further 
documentation was collected and the case reviewed in detail and 
adjudicated by a central Clinical Events Committee (CEC). MI was 
diagnosed on the basis of new ST segment elevations, new Q waves, or 
new or repeated CK-MB elevations above the ULN. Following 
percutaneous or surgical intervention, the elevation of CK-MB level was 
required to be at least 3–5 times the ULN. 
Data analysis 
The statistical analysis was performed using the SAS 8.0 software package 
(SAS Institute, Cary, NC, USA). Continuous variables are presented as 
mean values±standard deviation and dichotomous variables as 
percentages. One-way analyses of variance (ANOVA) and X2-tests were 
applied to evaluate differences in baseline characteristics, death, MI rates 
and rates of repeated coronary interventions (both at the 30-day and 6-
month follow-up) between the different subgroups classified according to 
the applied treatment strategy. In case of a statistically significant difference 
in clinical events or repeated coronary interventions, which was specified at 
the conventional p<0.05 level, repeated tests were performed to further 
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evaluate the inter-subgroup differences. The Bonferroni method [14] was 
used to avoid spurious significant results after multiple testing, and the level 
of significance was lowered to p<0.0167 and p<0.0083 in case of 3 (balloon 
– stent – surgery) and 6 possible comparisons (medical treatment – balloon 
– stent – surgery), respectively. 
Results
Patient characteristics 
During the first 30 days of randomization, a PCI was performed in 1,075 of 
3,067 (35%) patients, with stent placement in 542 cases (50% of the PCI 
procedures), whereas 1,091 of 3,067 (36%) patients underwent CABG. The 
remaining 901 (29%) patients were medically treated (figure 1). A 
significant difference was evident between the treatment subgroups with 
respect to age; medically treated and CABG patients were older than those 
undergoing PCI  (table 1). There were also differences regarding history of 
prior cardiovascular events and interventions. Almost one quarter of the 
PCI patients had a previous PCI versus 17 and 14% in the medical and 
surgical subgroups, respectively. A prior CABG was performed in 36% of 
medically treated patients, and this figure was only 9% in the CABG 
subgroup. A history of MI, heart failure, cerebrovascular accident, as well 
as peripheral vessel disease was more frequently observed in the medically 
versus non-medically treated patients. No important differences were 
observed in the use of cardiac medications except for the use of ACE 




Table 1: Clinical baseline characteristics. 
   






Demographics     
Mean age ± SD, years 65 ± 10 63 ± 11 62 ± 11 64 ± 10*** 
Male gender, % 70 74 73 73 
Caucasian, % 86 89 91 90* 
    
Medical history and risk 
factors 
    
Hypertension, % 62 60 61 57 
Diabetes mellitus, % 30 26 23 27 
Current smoker, % 28 29 29 26 
Hypercholesterolemia, % 50 46 53 47 
Prior PCI, % 17 23 23 14*** 
Prior CABG, % 36 24 29   9*** 
Prior MI, % 47 40 36 34*** 
Heart failure, % 14   8 10   6*** 
Prior CVA,%   7   4   5   3** 
Peripheral vessel disease, % 13   8   9   9** 
    
Cardiac medication prior to 
admission 
    
Aspirin, % 73 74 76 74 
Beta-blocker, % 48 50 49 49 
Calcium antagonist, % 39 34 36 36 
Nitrates, % 73 75 77 74 
ACE inhibitors, % 30 23 24 21*** 
    
Clinical presentation     
CK-MB  >1 ULN, % 52 52 44 48* 
ST depression  >0.5 mm, % 52 47 52 58*** 
ST elevation >0.5 mm, % 12 17 15 13* 
T wave inversion >0.5 mm, % 48 51 50 45 
ACE = Angiotensin converting enzyme; CVA = cerebrovasculair accident; other 
abbreviations, as defined in the text. Statistical test (integral comparison of 4 groups); 
*p<0.05;  **p< 0.01;  ***p<0.001. 
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Table 2:  Coronary angiography results. 
 Medical PCI CABG 
  balloon stent  
Vessel disease, %     
     2 38** 62** 61** 28*** 
     3 51 32 30 52 
  LM 11   6   9 21 
Significant stenosis (DS > 50%) in 
  RCA, % 84 79 81 85** 
  LAD, % 88 77 82 91*** 
  LCX, % 84 77 72 79*** 
  LM, % 12   6 10 22*** 
 Total occlusion (DS = 100 %) in    
  RCA, % 48 33 33 33*** 
  LAD, % 35 24 26 20*** 
  LCX, % 32 21 21 17*** 
Culprit artery, %     
  RCA 14 27 25 16*** 
  LAD 21 25 29 29*** 
  LCX 14 31 21   9 
  LM   2   1   1   9*** 
  Graft   9   8 14   3*** 
  None/unknown 40   8 10 34*** 
  Mean LVEF± SD 50 ±16 55 ±14 54 ± 14 53 ± 14*** 
DS = Diameter of stenosis; LAD = left artery, descending; LCX = left circumflex; LM = left 
main; LVEF = left ventricular ejection fraction; RCA = right coronary artery; other 
abbreviation, as defined in the text. Statistical test (integral comparison of 4 groups):  
**p<0.01;  ***p<0.001. 
Angiographic findings 
Patients who underwent CABG had more severe coronary artery disease 
(52% had 3-vessel and 21% left main disease), immediately followed by 
medically treated patients with a similar percentage of 3-vessel disease 
(51%) but less often, left main disease (11%) (table 2). A total occlusion in 




medically than in non-medically treated patients. Medically and surgically 
treated patients not only had more severe, but also more diffuse coronary 
artery disease than PCI patients, as in 34% (CABG) to 40% (medically 
treated) of the patients, the culprit artery could not be identified; this 
percentage was only 8–10% in PCI patients. Left ventricular ejection 
fraction was lowest among medically treated patients. There were no 
apparent differences in coronary angiography results between PCI patients 
receiving stents and those that did not receive stents. 
Clinical outcome 
The 30-day mortality rate was significantly higher among medically treated 
patients (6.7%) than among those undergoing PCI either with (2.4%) or 
without stent placement (3.9%) (figure 2). The observed difference in 
mortality rate (p value = 0.067) between medically treated and CABG 
patients (4.8% mortality) did not reach the required level of significance, 
which was prespecified as p<0.0083. 
The 30-day MI rate according to the opinion of the CEC was lower among 
medically than non-medically treated patients, with the highest event rate 
observed in the CABG group (27.7%); approximately half of the MIs in the 
PCI and CABG subgroups occurred within 48 h after the procedure. 
Differences in event rates as observed at 30 days were still present at the 
6-month follow-up. Mortality was highest in the medically treated subgroup 
(11.1%). Mortality rates were similar in the non-medical treatment 
subgroups (ranging from 5.5 to 6.5%). MI rates as judged by the CEC were 
lowest in the medically treated patients (20.8%) and highest in patients 
undergoing CABG (29.6%). 
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Repeat Revascularization Procedures 
Figure 2: 30-day (a) and 6-month (b) clinical outcome according to the treatment 
strategy applied. Black bars indicate mortality and white bars indicate MI adjudicated by 
the CEC.
p values for the overall comparison between any of the treatment strategies applied 
(medical treatment, balloon, stent or surgery) and each clinical endpoint are as follows: a
death: p=0.002, MI: p=0.001 both at 30 days and 6 months. 
Figure 3: 30-day (a) and 6-month (b) repeat revascularization procedures according to 
the treatment strategy applied. 
Black bars indicate PCI and white bars indicate CABG. p values for the overall 
comparison between any of the re-interventions and each group based on the treatment 
strategy applied initially (medical treatment, balloon, stent or surgery) are as follows: 




The rate of repeat revascularization at the 30-day and 6-month follow-up 
were significantly lower after CABG than after PCI (figure 3). Patients 
undergoing stent implantation during the initial PCI had lower CABG rates 
at each of these 2 points in time when compared to non-stented patients. 
No apparent differences were observed in the rates of repeat interventions 
between stented and non-stented patients. A substantial number of 
medically treated patients still underwent a PCI (4.6%) or CABG (15.4%) 
procedure between 1 and 6 months after admission. 
Discussion 
Patients who present with acute chest pain without persistent ST segment 
elevation represent a heterogeneous population, which spans from non-
cardiac chest pain (retrospectively diagnosed), to unstable angina and 
acute MI. The uncertainty in early clinical diagnosis forces clinicians to 
embark upon an empirical course of treatment, and this is the main reason 
why the clinical community still debates intensively regarding the optimal 
treatment strategy for patients with non-ST elevation acute coronary 
syndromes. Coronary angiography identifies patients with non-significant 
coronary stenoses and those with multivessel or left main disease. The 
former group has an excellent prognosis with a low risk of progression to MI 
or death, whereas the latter group, which is at an increased risk of 
progression to any of the aforementioned events, may derive a survival 
benefit from revascularization (either PCI or CABG) [15,16]. Patients who 
are not suitable candidates for standard revascularization or those who are 
at high risk of major peri-operative complications due to comorbid 
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conditions represent a distinct category in which medical treatment is 
preferred.
A major goal in PURSUIT was to understand the heterogeneity of the 
patient population and treatment strategies applied. The investigators 
therefore chose to embed the study of the effects of epifibatide in a real-life 
clinical setting including a broad spectrum of clinical practices, from rural 
hospitals to major tertiary referral centers around the world. To reflect 
actual clinical practice, no recommendations were made regarding the use 
and timing of coronary angiography, percutaneous coronary interventions 
or coronary bypass surgery, but all treatment decisions were left at the 
discretion of the team of treating physicians. Therefore, the results of the 
present descriptive analysis should be interpreted with this background in 
mind and viewed with the inherent limitations to subgroup analysis of 
randomized clinical trials [17]. 
Although not prospectively randomized to each of the treatment strategies 
compared, it is important to note that the medical therapy, early PCI and 
CABG ratio in these subgroups of 3,067 patients with an acute coronary 
syndrome and multivessel coronary artery disease was almost 1:1:1. 
Indeed, important differences were observed in clinical characteristics and 
coronary anatomy between the distinct subgroups. Patients who did not 
undergo a coronary intervention within 30 days after enrolment, generally 
were in a less favourable clinical condition than patients undergoing early 
invasive treatment. The relatively high 30-day and 6-month mortality rate 
among medically treated patients is therefore not surprising and argues for 
the search of better treatment strategies in unstable patients with 
multivessel coronary artery disease that are not good candidates for 




refrain from invasive treatment in this patient population seem to be 
comorbid conditions, left ventricular dysfunction (medically treated patients 
more often had a history of CABG, heart failure, and a worse left ventricular 
function as compared to CABG patients) and the extent of coronary artery 
disease (medically treated patients more often had 3-vessel and left main 
disease as compared to PCI patients). 
Limitations 
This was a retrospective assessment of clinical, angiographic 
characteristics and clinical events in patients enrolled in a multicenter 
clinical trial and stratified according to the treatment strategy applied with a 
follow-up limited to 6 months, which can be considered as the main caveat 
of this study. We lack data on anginal status at baseline and 6 months; and 
on other predictors of adverse outcome such as completeness of 
revascularization; in both PCI and CABG patients. There were insufficient 
data on post-procedural cardiac enzymes as well. However, the present 
analysis reflected standard practice in a wide range of clinical settings, and 
contemporary treatment strategies for the management of patients with 
acute coronary syndromes and multivesel disease were used in this trial.  
Conclusions
The observed major differences in clinical outcome are explained by an 
imbalance in baseline and angiographic characteristics between the groups 
of patients analyzed according to the treatment strategy applied. 
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Objectives: To assess long-term survival in unselected patients with 
coronary artery disease in who an invasive approach is considered. 
Methods: All patients with significant coronary artery disease who were 
presented for coronary revascularisation to two tertiary centres in 1992 
were included. Follow-up data were collected in September 2002. 
Multivariate Cox’ proportional-hazards regression analysis was applied to 
assess the independent relation between variables and 10-year survival. 
Results: A total of 877 patients were included in this analysis. Mean age 
was 62 and the most common clinical diagnosis was chronic stable angina 
(60%). Diabetes was present in 12% of the patients. During the follow-up 
period, a total of 233 patients (27%) died. Predictors of long-term survival 
were increasing age, diabetes, peripheral vascular disease and a 
decreased left ventricular function. Compared to medical treated patients, 
those treated with revascularisation (either by PCI or CABG) had a 
decreased long-term mortality (p<0.05). Of the patients with PCI 27% had 
died, compared to 24% in those who had CABG and 36% of those who 
were treated medically. However, after adjusting for differences in baseline 
variables, conservative treatment was no significant predictor of long-term 
mortality. After multivariable analyses, increasing age, decreased left 
ventricular function and diabetes were independent predictors of long-term 
mortality.
Conclusions:  In patients with coronary artery disease in whom an invasive 
approach is considered, increasing age, impaired left ventricular function 
and diabetes are the strongest predictors of long-term mortality. After 
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adjustments for differences in baseline variables, invasive treatment is not 
associated with a lower long-term mortality. 
Introduction
Several medical treatments of coronary artery disease reduce mortality [1-
4] . Long-term results after an invasive approach, however, are conflicting 
and may differ between Coronary Artery Bypass Surgery (CABG) and 
Percutaneous Coronary Intervention (PCI) [5-8]. In a meta-analysis of all 
randomised controlled trials comparing CABG with PCI, CABG was 
associated with lower five-year mortality, less angina, and fewer recurrent 
revascularisation procedures [9]. However, most of these trials had 
important limitations. Approximately two-thirds of the eligible patients were 
excluded because of angiographic finding, such as chronic total occlusions, 
complex stenoses, left main coronary artery disease, or the inability to 
achieve adequate revascularisation. Patients with recent myocardial 
infarction or previous revascularisation were often excluded as well. So, 
these results concerned selected patients and may be not comparable to 
results observed in daily practice. Data from registries or a consecutive 
patient population may provide more insights in long-term outcome after 
coronary revascularisation. However, many data from registries, such as 
from the Coronary Artery Surgery Study (CASS) Registry are of older date 
and may not reflect the present state of the art [10,11]. 
To evaluate long-term prognosis of patients with coronary artery disease in 
daily practice, we did a long-term follow-up study of patients included in the 




study. In particular, we assessed the association between type of 
revascularisation (CABG or PCI) and mortality. 
Methods
The DUCAT study aimed to determine the appropriateness of decisions to 
offer patients with coronary artery invasive or medical treatment [12]. The 
appropriateness of decisions was assessed using the RAND/UCLA method 
[13]. The DUCAT expert panel consisted of six cardio-thoracic surgeons 
and 6 interventional cardiologists of the 12 heart centers in the 
Netherlands. This panel method proved to be consistent and reliable in 
assessing appropriateness. 
Enrolment began in February 1992 for a period of 3 months. Each case 
was presented by the patient’s cardiologist in person or by letter, fax, or 
telephone, and eventually led to an intention to treat decision in favour of 
PCI, CABG, or medical treatment. All presentations were based on 
coronary angiographic results, showing significant coronary artery disease, 
defined by the DUCAT panel as at least 50% narrowing of the left main 
artery or 70% in other arteries. Patients who previously had had CABG or 
for whom CABG was to be combined with other surgery (cardiac or 
general) were excluded. At the time of presentation to the heart team, key 
patient data were collected, including demographics, medical history, risk 
factors for coronary artery disease, symptomatology, medication, ischemia 
detection tests, coronary angiographic evaluation, left ventricular function 
tests, urgency status and intention of treatment. The main findings of the 
DUCAT study have been published previously [12,13]. In summary, 3646 
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consecutive patients were included. Unstable angina was the clinical 
condition associated with the highest proportion of appropriate intention-to-
treat decision, whereas in asymptomatic coronary disease the rate of 
appropriate decisions was lowest. 
The present study is a two-center follow-up study of all patients 
consecutively presented to the heart centers of Zwolle and Groningen in 
the Netherlands. In these two centers, a total of 1047 patients were 
presented to the cardio-pulmonal teams. 
Follow-up data were obtained on the vital status up to ten years after 
inclusion. Follow-up data were collected via the register office, the General 
Practitioner or via a direct contact with the patient or his relatives by 
telephone.
Statistics
Differences between group means were tested by two-tailed Student's         
t-test. A Chi-square statistic was calculated to test differences between 
proportions. Survival functions were calculated, using the Kaplan-Meier 
product limit method [14]. Mantel-Cox (or log-rank) test was applied to 
evaluate the differences between survival functions [15]. 
Multivariate Cox’ proportional-hazards regression analysis was applied to 
describe the independently relation between variables and 10-year survival. 
Statistical significance was defined as a p-value of less than 0.05. The 
Statistical Package for the Social Sciences (SPSS Inc, Chicago, IL, USA) 






During enrolment, a total of 1047 patients were presented to the two heart 
centers for the first time. Of these patients, 877 patients (84%) met the 
inclusion criteria and were enrolled in the study. Mean age of the patients 
was 62.4 years (SD 9.6). Females were older than males, 66 years vs. 61 
years respectively (p<0.01). The most common clinical diagnosis was 
chronic stable angina (60%). Anti-ischemic medication was used by 94% of 
the patients. A history of myocardial infarction was reported in 37% and 
29% had hypertension. Diabetes was present in 12% of the patients. 
Table 1: Baseline characteristics of 877 patients according to revascularisation type.
    
Characteristic PCI CABG Medical therapy 
    
No 376 384 117 
Mean age (yr)   61 r 10   63 r 9* 63 r 11 
Males 263 (69.9%) 299 (77.9%)# 90 (76.9%) 
Diabetes   39 (10.5%)   51 (13.3%) 17 (14.7%) 
Previous MI 164 (43.9%) 194 (50.9%)# 69 (59.0%)* 
Previous PCI   52 (13.9%)   33   (8.6%) 11   (9.4%) 
COPD *   30      (8%)   36   (9.4%) 12 (10.3%) 
Hypertension 117 (31.4%) 114 (29.8%) 27 (23.1%) 
Peripheral vasc. disease   29   (7.8%)   39 (10.2%) 19 (16.2%)#
Smoking 114 (33.1%)   81 (23.3%)# 31 (29.2%) 
Hypercholesterolaemia 117 (33.9%) 149 (41.9%) 30 (29.7%) 
Single vessel disease 231    (61%)   17 (  4.4%)* 58    (50%)#
Left main stenosis     3   (0.8%)   55    (14%)*   3   (0.8%)  
Poor LV function     9   (2.5%)     5   (1.3%) 11   (9.5%)* 
Unstable 153 (41.2%) 118 (31.4%)* 15   (3.2%)*
CCS III, IV 118 (31.8%) 141 (37.5%) 51 (44.7%)#
CCS I, II, (Atyp, Asym)   77 (20.8%) 115 (30.6%)* 47 (41.2%)* 
Acute MI   23   (6.2%)     2   (0.5%)*   1   (0.9%)#
Type C lesion 109    (29%) 259 (67.4%)* 75 (64.1%)*
Prox Lad lesion 131 (34.8%) 229 (59.6%)* 40 (34.2%) 
Difference with ‘PCI’ significant at p<0.05 (#) or p<0.01 (*). 
CVA = Cerebro Vasculair Accident; COPD = Chronic Obstructive Pulmonary disease. 
CCS  = Canadian Cardiovascular  Society. 
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Angiography and revascularisation 
Of the included patients, 30% had three-vessel disease. Left ventricular 
(LV) function was normal in 81%, whereas 16% had moderately decreased 
LV function and 3% had a severely depressed LV function. 
For 376 patients (43%) the cardiopulmonal team preferred PCI as 
appropriated for 384 patients (44%) CABG and for 117 patients (13%) 
medical therapy. Table 1 shows the differences in baseline characteristics 
between the three treatment groups. Patients treated with PCI were 
younger, were more often female, and had more frequently unstable 
coronary artery disease, less extensive coronary artery disease. Medical 
therapy was more often preferred for patients with complex lesions, 
previous myocardial infarction, peripheral vessel disease and poor left 
ventricular function. As expected, patients treated with CABG had more 
extensive coronary artery disease. 
Long-term mortality 
During the 10-years follow-up period, a total of 233 patients (27%) died. 
Table 2 presents the association between baseline characteristics and 
long-term mortality. In these univariate analyses, increasing age, unstable 
coronary artery syndrome, diabetes, peripheral vascular disease, and poor 
left ventricular function at baseline were statistically significant predictors of 
long-term mortality. Patients scheduled for medical treatment had a higher 
long-term mortality than patients scheduled for an invasive approach. Of 
the patients for whom PCI was recommended, 27% had died during follow-
up, compared to 24% for CABG and 36% for medical treatment (p<0.05). 
Survival of the patients according PCI, CABG or medical treatment is 




Table 2: Predictors of long-term mortality in univariate analysis
Variable Odds Ratio 95% confidence interval 
Male gender 0.907 0.64 - 1.27 
Revascularisation 0.599 0.40 - 0.91 
Age (year) 1.103 1.08 - 1.13 
Previous MI 1.096 0.82 - 1.48 
Hypertension 1.141 0.82 - 1.58 
Diabetes mellitus 1.724 1.13 - 2.64 
Periph. vasc. disease 2.026 1.28 - 3.20 
Smoking 0.986 0.69 - 1.41 
COPD 1.260 0.76 - 2.09 
Single vessel disease 0.992 0.73 - 1.36 
Left main stenosis 1.128 0.63 - 2.02 
Poor LV function 3.229 1.45 - 7.19 
Unstable angina 0.963 0.70 - 1.33 
CCS III, IV 1.328 0.97 - 1.81 
CCS I, II, atypical 0.671 0.47 - 0.96 
Acute MI 1.747 0.78 - 3.91 
Pos concl stress test 2.009 1.09 - 3.71 
Prox Lad 0.883 0.65 - 1.19 
Type C lesion 1.106 0.82 - 1.49 
Nitrates 0.903 0.65 - 1.26 
Betablockers 0.909 0.67 - 1.24 
Figure 1: Long-term mortality 
of 877 patients according to 
medical treatment, CABG or 
PCI.
Medical compared to PCI: 
P value = 0.0201 
CABG compared to PCI:  
P value = 0.5180 
Medical compared to CABG: 
P value = 0.0268 
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Table 3: Predictors of long-term mortality after multivariate analysis. 
Variable Odds Ratio 95% confidence interval 
Male gender 1.36 0.98 - 1.89 
Age (per year) 1.09 1.07 - 1.12 
Conservative treatment# 1.24 0.86 - 1.79 
Decreased LV function 1.58 1.15 - 2.18 
Diabetes 1.46 1.01 - 2.13 
Periph. Vasc. Disease 1.28 0.85 - 1.91 
#As compared to revascularisation by either PCI or CABG. 
 Adjusted for differences in the other variables. 
The predictors of long-term mortality differed between the groups of 
patients treated conservative, by CABG or by PCI. Admission with an acute 
coronary syndrome or decreased left ventricular function (OR 1.73; 95% CI 
1.09-2.29) were predictors of higher mortality in patients scheduled for 
CABG. Diabetes was particularly a predictor of mortality in patients 
scheduled for PCI or medical treatment (OR 2.33; 95% CI 1.51-3.59). 
Patients with hypertension or unstable angina had a higher mortality after 
medical treatment. Peripheral vascular disease predicted mortality in 
patients scheduled for PCI more strongly than in patients treated by CABG 
of medically.
Multivariable analyses 
To adjust for potential confounders, multivariable analyses were performed. 
Adjustments were made for age, gender and statistically significant 
predictors of long-term mortality in the univariate analyses. In the 
multivariable model, age, gender, revascularisation, diabetes,  peripheral 
vascular disease and decreased left ventricular function were included. The 




impaired left ventricular function and diabetes were independent, significant 
predictors of long-term mortality. Revascularisation was not statistically 
significant associated with a lower mortality. 
Discussion 
In this retrospective analysis of unselected patients with coronary artery 
disease presented for an invasive approach, independent predictors of 
long-term mortality were increasing age, impaired left ventricular function 
and diabetes. After adjustments for differences in baseline variables, 
invasive treatment by either PCI or CABG was not associated with a lower 
long-term mortality. 
Although randomised clinical trials are the gold standard for evidence 
based medicine, extrapolation of the results to the general patient 
population should be done with caution. In most randomised trials, many 
patients are excluded and crossover between treatment groups is common. 
Therefore, data from cohort studies concerning patients seen in daily 
practice remain an important source of information. 
In our study,  patients with conservative treatment had not a significant 
increased risk of long-term mortality after multivariable analyses. These 
findings are in line with the results of several previous studies. In the latest 
meta-analysis of all randomised studies comparing CABG and PCI, in 
patients with single vessel disease there was no significant survival benefit 
after CABG after eight years follow-up [9]. Also in the RITA-II trial the 7-
years survival curves of patients randomised to PCI or medical treatment 
overlapped [16]. Furthermore, the meta-analysis including the VA, 
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European Co en CASS showed after a 10-year follow-up period 
comparable mortality for patients randomised to CABG. Also, the results of 
revascularisation in patients with an acute coronary syndrome are not clear. 
In the OASIS registry, evaluating approximately 8000 patients with 
suspected unstable angina or myocardial infarction without initial ST 
elevation from 6 countries, after revascularisation a reduction in refractory 
ischemia and need for hospitalisation was observed, but not a decrease of 
mortality [17]. 
The lack of survival benefit of revascularisation in our analysis may have 
several explanations. Revascularisation may be beneficial only after short 
or intermediate follow-up, whereas after long-term follow-up mortality is 
comparable between patients with and without revascularisation. Another 
explanation is that patients allocated to invasive treatment have more 
unfavourable prognostic characteristics at baseline. Although also in our 
study, multivariable analyses were performed, these multivariable 
adjustments can not correct for all patient characteristics, and does not rule 
out the effect of selection of patients who are candidates for 
revascularisation, and those who are not. 
Diabetes was an independent predictor of long-term mortality in our total 
study population, but in particular in patients scheduled for medical 
treatment or PCI. The better prognosis of patients with diabetes who were 
treated by CABG may be due to more complete revascularisation [18],  
particularly if the internal mammarian artery (IMA) is used [19]. PCI may be 
less effective in diabetic patients because of smaller caliber vessels and a 
high incidence of restenosis [20]. In contrast, the long-term patency of an 




[21]. Furthermore, patients  treated with PCI in our study, were treated only 
with balloon, and especially in patients with diabetes use of (drug-eluting) 
intracoronary stents may improve prognosis after PCI. 
In all subgroups in our study, an impaired left ventricular function was 
associated with increased long-term mortality. Apart from treatment of 
myocardial ischemia by revascularisation, medical treatment may be of 
benefit in these patients, including beta-blockers and ACE-inhibitors. 
Probably, use of implantable cardiodefibrillators can also improve long-term 
survival in these patients [22]. 
Peripheral vascular disease was a predictor of long-term mortality, 
particularly in patients scheduled for PCI. In the total study group peripheral 
vascular disease was not an independent significant predictor of long-term 
mortality after multivariable analyses. Peripheral vascular disease may be 
associated with more extensive and diffuse coronary artery disease [23].  
Limitations 
Our study has several limitations. Because the sample size of the study 
was not very large, the number of patients in the subgroups were small. We 
had no data on major cardiac events as myocardial infarction or additional 
revascularisation during the follow-up period. There was also no 
information on use of medication or anginal status during the follow-up 
period. The cause of death could not be traced in our majority of patients. 
Of course, during the 10-year follow-up period, treatment strategies 
changed and new interventions were introduced. CABG and PCI 
techniques improved, including off-pump surgery and the use of (coated) 
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stents and GP IIb/IIIa inhibitors in PCI. Medical treatment improved too, 
with more frequent use of statins, beta-blockers and ACE-inhibitors. We did 
an observational study, and some of our observations, including mortality 
differences between invasive and conservative treated patients may have 
been caused by patient selection. 
Conclusions
1. In patients with coronary artery disease in who an invasive approach is 
considered, increasing age, decreased left ventricular function and diabetes 
were the most strong predictors of long-term mortality. 
2. Invasive treatment  was not associated with lower long-term mortality 
after multivariable analyses. Although in the analyses adjustments were 
made for several potential confounders, these findings may, however, be 
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Aims: The optimal method of revascularisation in diabetic patients with 
coronary artery disease remains controversial. It was our aim to evaluate 
long-term outcome of diabetic patients with coronary artery disease in daily 
practice in whom an invasive approach was considered. 
Methods: It concerns a prospective follow-up study of patients with 
coronary artery disease in whom a coronary revascularisation procedure 
was considered. Follow-up data were obtained on the vital status up to ten 
years after inclusion.  
Results: Of the 872 included patients, a total of 107 patients (12%) had 
diabetes. Patients with diabetes were older and more frequently female. 
Long-term mortality was higher in diabetes compared to non-diabetes (36% 
vs. 25%, p=0.01). This association was observed in both medical treated 
patients (65% vs. 31%, p=0.01) and in those treated with percutaneous 
coronary intervention (41% vs. 24%, p=0.02). There was, however, no 
difference in mortality in diabetes versus non-diabetes after coronary artery 
bypass grafting (24% vs. 24%, p=0.89). Multivariate analysis did not 
change these findings.
Conclusions: In patients with coronary artery disease in whom an invasive 
approach is considered, diabetes is associated with a higher long-term 
mortality. After coronary artery bypass grafting, long-term survival may be 
comparable between patients with and without diabetes.         




Diabetes is associated with impaired outcome after coronary 
revascularisation [1,2] The optimal method of revascularisation remains 
controversial. In the BARI trial, coronary artery bypass grafting (CABG) 
when compared to percutaneous coronary intervention (PCI), was 
associated with a significant 7-year mortality reduction in patients with 
diabetes [3]. However, this long-term benefit was not confirmed by other 
randomised trials [4,5] Furthermore, patients in daily practice may differ 
from those included in randomised trials, as was shown in the registry of 
the BARI trial [6]. To evaluate long-term outcome of diabetic patients with 
coronary artery disease (CAD) in daily practice in whom an invasive 
approach was considered, we did a follow-up study of patients included in 
the DUCAT (DUtch inventory of invasive Coronary Atherosclerosis 
Treatments) study.
Patients and Methods 
The DUCAT study (DUtch inventory of invasive Coronary Atherosclerosis 
Treatments) was initiated in 1992 with the purpose to determine how 
appropriate treatment decisions are concerning invasive treatment of 
patients with CAD [7]. Assessment of appropriateness of medical decisions 
was achieved using the RAND/UCLA method [8]. Six cardio-pulmonal 
surgeons and 6 interventional cardiologists of 12 heart centres in the 
Netherlands were asked to participate in a panel to determine 




presented to 10 heart teams consisting of at least one surgeon and one 
interventional cardiologist. This panel method has been proven to be 
consistent and reliable in assessing appropriateness [8]. 
Enrolment began in February 1992 for a period of 3 months. Each case 
was presented by a clinical cardiologist in person or by letter, fax, or 
telephone, and eventually led to an intention to treat decision in favour of 
PCI, CABG, or medical treatment.  All presentations were based on clinical 
data and coronary angiographic results. Enrolment was approved for all 
patients with significant CAD, defined by the DUCAT panel as a minimum 
of 50% narrowing of the left main artery in left main disease, at least one 
artery with 70% narrowing and other arteries with 50% narrowing in 
multivessel disease, and one artery with 70% narrowing in one-vessel 
disease. Patients who previously had CABG or in whom CABG was to be 
combined with other surgery (cardiac or general) were excluded. During 
presentation at the heart team, several variables were collected, including 
demographics, medical history, risk factors for CAD, symptomatology, 
medication, ischemia detection tests, coronary angiographic evaluation, left 
ventricular function tests, urgency status and intention of treatment. The 
main findings of the DUCAT study were published previously [7,8]. In 
summary, 3646 consecutive patients were included. Unstable angina was 
the most appropriate clinical status for intervention, whereas asymptomatic 
coronary disease was the least. 
The present study is a two centre follow-up study of all patients 
consecutively presented to the cardio-pulmonal team of the heart centres of 
Zwolle and Groningen in the Netherlands. In these two centres, a total of 
1047 patients were presented to the cardio-pulmonal teams during the 
study period. Follow-up data were obtained on the vital status up to ten 
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years after inclusion. Follow-up data were collected via the register office, 
the General Practitioner or via a direct contact with the patient or his 
relatives by telephone. 
Statistics
Differences between group means were tested by two-tailed Student's         
t-test. A Chi-square statistic was calculated to test differences between 
proportions. Survival functions were calculated, using the Kaplan-Meier 
product limit method. Mantel-Cox (or log-rank) test was applied to evaluate 
the differences between survival functions. 
Multivariate Cox’ proportional-hazards regression analysis was applied to 
assess the independent relation between revascularisation strategy and 10-
year survival after adjustment for baseline characteristics. 
Results
Patients
Of the 1057 included patients, 10 cases were censored because they were 
presented to the cardio-pulmonal team for the second time. Of the 
remaining 1047 patients, 877 (84%) met the inclusion criteria and were 
enrolled in the study. Of 5 patients the diabetic status was unknown, these 
patients were not included in our analysis. Our analysis consisted therefore 
of 872 patients. A total of 107 patients (12%) had diabetes. Patients with 
diabetes were older (66r8 vs. 62r10 year, p<0.001), were more frequently 
female (55% vs. 21%, p<0.001) and had a higher prevalence of 




diabetes. Furthermore, patients with diabetes had more often multi vessel 
disease. Differences in baseline characteristics between patients with and 
without diabetes are shown in table 1. 
Table 1: Baseline characteristics of all patients according to diabetic status.
    
 Diabetes Non-diabetes p value 
N: 107 765  
    
Age in yr. (mean (SD)) 66 r 8   62 r 10 < 0.001 
Male 48 (44.9%) 601 (78.6%) < 0.001 
    
Risk factors    
     Hypertension 49 (45.8%) 208 (27.3%) < 0.001 
     Smoking 17 (18.9%) 209 (29.7%)    0.033 
     Lipid disorder 35 (35.7%) 261 (37.1%)    0.786 
     Family history  24 (28.9%) 278 (42.4%)    0.018 
     Obesity 17 (21.3%)   77 (13.2%)    0.054 
    
Coronary history    
     Previous MI 35 (32.7%) 292 (38.3%)    0.266 
     Previous PCI  13 (12.1%)   83 (10.9%)    0.694 
    
Co-morbidity    
     COPD 12 (11.2%)   66   (8.7%)    0.389 
     Periph Vasc Disease 17 (15.9%)   70   (9.2%)    0.030 
     Stroke 12 (11.2%)   41   (5.4%)    0.018 
    
Vessels diseased    
     One vessel 28 (26.2%) 275 (35.9%)    0.047 
     Two vessel 36 (33.6%) 214 (28.0%)    0.224 
     Three vessel 37 (34.6%) 223 (29.2%)    0.250 
     Left Main   6   (5.6%)   53   (6.9%)    0.610 
     Type C lesion 58 (54.2%) 382 (49.9%)    0.408 
    
LVEF 20 – 40% 17 (16.3%) 116 (15.6%)    0.843  
      <20%   5   (4.8%)   20   (2.7%)    0.218 
COPD = chronic obstructive pulmonary disease, MI = myocardial infarction, PCI = 
percutaneous coronary intervention, SD = standard deviation. 




In patients without diabetes, PCI was recommended in 333 patients (44%),  
CABG in 333 patients (44%) and a conservative approach was advised in 
99 patients (13%). In patients with diabetes the type of revascularisation 
was comparable to those without diabetes, with percentages of patients 
recommended for PCI, CABG or conservative approach of 36%, 48% and 
16%, respectively. There were several differences between diabetic 
patients treated conservatively and treated invasively. Patients with 
diabetes treated with PCI had more often single vessel disease (56% vs. 
4%, p<0.001) compared to those treated with CABG. LVEF was 
comparable between PCI and CABG treated patients.
Long-term mortality  
In the total study group, long-term mortality was associated with increasing 
age, revascularisation, diabetes (36% vs. 25%, p=0.01), peripheral artery 
disease and a LVEF < 20%. As compared to revascularisation by either 
PCI or CABG, medical treated patients had an increased mortality. The 
increased mortality in patients with diabetes was observed in both medical 
treated patients (n=116) (diabetes 65% vs. non-diabetes 31%, p=0.01) and 
in those who received PCI (n=372) (diabetes 41% vs. non-diabetes 24%, 
p=0.02). There was, however, no difference in mortality between diabetes 
and non-diabetes after CABG (n=384) (24% vs. 24%, p=0.89). Survival 
curves of patients with and without diabetes according to type of 





To study the independent prognostic importance of diabetes on clinical 
outcome, multivariate analysis was performed. We included age, gender 
and all univariate predictors of long term mortality in the multivariate model. 
After multivariate analysis increasing age, diabetes and a decreased LV 
Figure 1: 10-year follow-up of 116 
medically treated patients.  
Figure 2: 10-year follow-up of 372 
PCI treated patients. 
Figure 3: 10-year follow-up of 384 
CABG treated patients. 
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function were independent predictors of long-term mortality (table 2). The 
independent predictive value of diabetes was most pronounced in patients 
treated without revascularisation and in those treated with PCI (OR 2.1; 
95% CI 1.3 to 3.3). In patients treated with CABG, diabetes was no 
independent predictor of long term mortality (OR 1.2; 95% CI 0.6 to 2.4).  
Discussion 
In patients with coronary artery disease in whom an invasive approach is 
considered, diabetes is associated with increased long term mortality. 
However, in patients treated with CABG this association was not observed. 
Our analysis reflects real world clinical practice and has additional value 
regarding the still ongoing debate about the optimal method of 
revascularisation of patients with diabetes. 
Table 2: Predictors of mortality in patients in the DUCAT study.
 OR 95% CI 
Male gender   1.36 0.98 to 1.89 
Age (per year)  1.09 1.07 to 1.12 
Conservative treatment# 1.24 0.86 to 1.79 
Diabetes  1.46 1.01 to 2.13 
Periph. Vasc. Disease  1.28 0.85 to 1.91 
Decreased LV function 1.58 1.15 to 2.18 
#As compared to revascularisation by either PCI or CABG. Adjusted for differences 
in the other variables.  




Diabetes versus non-diabetes 
Patients with diabetes had a higher long term mortality compared to 
patients without diabetes. This could be due to differences in baseline 
characteristics. In general, patients with diabetes were older, were more 
often female and had a higher prevalence of hypertension. However, after 
multivariate analysis diabetes was still a significant predictor of mortality. 
There may be several mechanisms for this increase in mortality. A 
procoaguable state and more unfavourable lipid levels in diabetic patients 
might play a role [9,10]. Atherosclerotic coronary abnormalities may be 
more progressive in diabetes. Furthermore, pre existing left ventricular 
failure, either diastolic or systolic, may contribute to an increase in mortality 
[11]. Moreover, glycometabolic disturbances during acute coronary events 
increase infarct size and might predispose to ventricular arrhythmia’s [12]. 
Interestingly, in patients with extensive CAD, whom are generally treated 
with CABG, the difference in mortality between diabetes and non-diabetes 
seems to be much less clear [13].
PCI as revascularisation strategy 
Mortality was higher in PCI treated patients with diabetes compared to 
those without diabetes. There may be several explanations for this 
difference. Patients with diabetes have smaller calibre vessels and higher 
rates of restenosis than patients without diabetes [14]. Furthermore, more 
progressive atherosclerosis in diabetes may also affect coronary segments 
not significantly stenosed at the time of the initial decision of 
revascularisation. As diabetic patients already have a comprised LV 
function, display impaired preconditioning and have glucometabolic 
disturbances potentially increasing ischemic myocardial damage, they 
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might be more prone to die when suffering subsequent coronary events 
[11,15].
CABG as revascularisation strategy 
There was no difference in mortality in diabetic patients treated with CABG 
compared to non-diabetic patients treated with CABG. Previous studies 
show conflicting results. Several studies report that diabetes is associated 
with a worse outcome after CABG [1,16]. The randomised EAST trial and 
the recently published study of Calafiore et al. however, did not find an 
association between diabetes and an long term adverse prognosis after 
CABG [5,17].
Revascularisation in diabetes 
In patients with diabetes, those treated medically had highest mortality, 
whereas the lowest mortality was found in diabetic patients treated with 
CABG. Differences in baseline characteristics between medical treated 
patients and those treated with revascularisation, may partly explain the 
differences in outcome. Medically treated patients were older and had a 
higher prevalence of peripheral artery disease and COPD than those 
treated with coronary revascularisation. The improved prognosis after 
CABG in diabetic patients can be caused by the fact that PCI in diabetes is 
associated with a higher restenosis rate, whereas graft patency after 4 
years between patients with and without diabetes may be comparable.[18] 
Also, incomplete revascularisation might be detrimental in diabetic patients 
treated with PCI. Coronary artery bypass grafting may be superior in 
reaching complete revascularisation  leaving PCI treated patients with an 




seems to be a protective effect from the use of an internal thoracic artery 
(ITA) in CABG, especially in patients with diabetes [20]. The mortality risk 
after myocardial infarction in diabetic patients without ITA is much higher 
when compared to diabetic patients who had received revascularisation 
with an ITA [20]. In our study the majority of patients were treated with an 
ITA.
Other studies 
In the BARI trial, 1829 patients with multivessel disease were randomised 
towards CABG or PCI [3]. This study found a better 7-year survival in 
diabetic patients (n=353) treated with CABG compared to PCI (76% vs. 
56%). However, other randomised trials, as the CABRI trial and the EAST 
trial, did not find a significant beneficial effect after CABG compared to PCI 
in diabetic patients [4,5]. Moreover, the RITA trial including 62 patients with 
diabetes found a non-significant worse outcome for diabetic patients 
randomised to CABG compared to PCI [21]. Observational studies also 
found contradicting evidence regarding optimal method of reperfusion. The 
Duke and EMORY analyses did not find a benefit of CABG versus PCI in 
diabetic patients, although insulin treated diabetes seemed to benefit from 
CABG [1,2]. The MAHI study found an unadjusted survival benefit of 
diabetic patients when treated with CABG compared to PCI.[22] 
Interestingly, in diabetic patients from the registry of the BARI trial there 
was no significant difference in mortality between the two revascularisation 
methods [6].  Niles et al. however did find a significant reduction in mortality 
in more than 7000 diabetic patients treated with CABG versus PCI after 5 
years follow-up [23]. Our study also did find a survival benefit of diabetic 
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patients when treated with CABG compared to PCI after a long follow-up 
period of 10 years.  
Study limitations  
This was an observational study without randomisation. This could have led 
to differences in unmeasured baseline characteristics for which no 
correction or adjustment could be made.   
Unfortunately, no information about the type of anti-diabetic treatment was 
available. During the study period, intracoronary stenting and treatment 
with glycoprotein IIb/IIIa inhibitors or clopidogrel were not available. These 
new therapeutic modalities may well have a profound effect on clinical 
outcome  and may, in particular, improve clinical outcome in patients with 
diabetes when treated with PCI [24,25].     
Conclusion
Diabetic patients with significant CAD have a higher long-term mortality 
compared to patients without diabetes. After CABG however, survival is 
comparable between diabetic and non-diabetic patients. Complete 
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Objectives: To assess determinants of clinical decision-making in patients 
with stable coronary artery disease. 
Methods: The 2936 patients with stable angina pectoris who enrolled the 
Euro Heart Survey on Coronary Revascularization were subject of this 
analysis. After the diagnosis has been confirmed, physicians decided upon 
treatment: medical management, or revascularization therapy by 
percutaneous coronary intervention (PCI) or coronary bypass surgery 
(CABG). We applied logistic regression analyses to evaluate the relation 
between baseline characteristics and treatment decision: medical treatment 
versus PCI, medical treatment versus CABG and PCI versus CABG. 
Results: Median age was 64 years, 77% were men and 20% had diabetes. 
Medical therapy was intended in 690 (24%), PCI in 1503 (51%), and CABG 
in the remaining 743 (25%) patients respectively. Revascularization was 
generally preferred in patients with more severe anginal complaints, an 
intermediate to large area of myocardium at risk, and a preserved left 
ventricular function, who had not undergone prior coronary 
revascularization, provided lesions were suitable for treatment. CABG was 
preferred over PCI in multivessel or left main disease, as well as in those 
with concomitant valvular heart disease, provided a sufficient number of 
lesions were suitable for CABG. In those with previous CABG, more often 
PCI was prefered than re-CABG. Diabetes was not associated with more 
often preference for CABG. 
Conclusion: The EHS-CR revealed that treatment decisions in stable CAD 
were largely in agreement with professional guidelines and determined by 
multiple factors. Most important deviations between guideline 
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recommendations and clinical practice were seen in patients with extensive 
coronary disease, impaired left ventricular function and those with diabetes. 
Introduction
In the Western World, stable coronary disease is a common and disabling 
disorder. Treatment aims to minimize or abolish symptoms, to prevent 
disease progression, and to improve prognosis by reducing the risk of 
myocardial infarction or death. According to current treatment guidelines 
patients should receive cardio-protective pharmaco-therapy, including anti-
platelet, anti-thrombotic and lipid-lowering agents, as well as anti-anginal 
medication. In selected patients, coronary revascularization by either 
percutaneous coronary intervention (PCI) or coronary artery bypass 
grafting (CABG) may be appropriate. In the absence of symptomatic 
indication, revascularization is recommended in patients with left main 
disease, multivessel disease, significant disease of the proximal part of the 
left anterior descending (LAD) artery, and in patients with a fair amount of 
viable myocardium at risk. CABG is preferred in patients with diabetes, 
those with more extensive disease, impaired left ventricular function, and in 
patients with anatomy that is not suitable for PCI [1-11]. 
The European Society of Cardiology (ESC) realized that the clinical 
management of cardiac patients in daily practice may vary from treatment 
guidelines. A broad range of clinical and lesion-specific characteristics may 
play a role in shaping treatment decisions in the real world. In order to 
obtain quantitative information on the adherence to European and 




Euro Heart Survey (EHS) program (extensive information regarding this 
program is available on the www) [12]. The EHS on coronary 
revascularization (EHS-CR), which was conducted in 2001-2002, with 
follow-up in 2003, enrolled 3006 consecutive patients with documented 
stable coronary disease undergoing coronary angiography. This well-
characterized study population provides a unique opportunity to conduct a 
systematic analysis of the relation between patient characteristics and 
choices about patient management. 
Methods
Patients
The EHS-CR has been described in detail elsewhere [12,13]. Briefly, the 
survey was designed to screen all consecutive patients undergoing 
invasive coronary diagnostic or therapeutic procedures. Patients were 
enrolled if they had a diameter stenosis of at least 50% in at least one 
major epicardial coronary artery. Data were then sent to a central database 
in the European Heart House (Sophia Antipolis, France) via the www, using 
the MacroTM software (InferMed, UK). The collected data included 
demographics, co-morbidity, diagnosis, and detailed information regarding 
diagnostic angiography and treatment modalities. Clinical outcome and 
complications were recorded during the initial hospitalization and at one-
year follow-up. Via the applied software, data were automatically checked 
for completeness, internal consistency and accuracy. The data 
management staff at the European Heart House performed additional edit 
checks. If necessary, queries were resolved with the local data collecting 
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officers. Between November 1, 2001 and March 1, 2002 a total of 5767 
patients were enrolled. Follow-up was obtained at 11 months after 
enrolment. The current analysis is limited to the 3006 (52%) patients with 
stable angina as primary diagnosis. 
Treatment decisions 
The EHS-CR is a descriptive study, and the survey protocol did not dictate 
any treatment decision. In general, physicians were encouraged to treat 
their patients in conformance with the most recent guidelines. In order to be 
informed of the physicians preferred, intended treatment, the survey 
included the following question: As the treating physician, which treatment 
option would be your first choice? According to the reply to this question, 
patients were classified with a physician’s intention for medical treatment, 
PCI, or CABG. 
Data description and data analysis
Continuous data are described as median values with corresponding 25th 
and 75th percentiles, and dichotomous data are described as counts and 
percentages. Differences in baseline clinical and angiographical 
characteristics in subgroups of patients according to intended treatment 
were analyzed by unpaired Student’s t-tests, analyses of variance 
(continuous data) and Chi-square tests (dichotomous data) as appropriate. 
All statistical tests were 2-sided, and significance was stated at P=0.05. 
Altogether 893 patients (30%) had missing data on at least one of the 
variables that were considered as potential determinants of treatment 
decisions (table 1). Simple missing data imputation was therefore applied, 




multivariable logistic regression analyses were then applied to further 
evaluate the relation between a broad range of baseline characteristics and 
intended treatment. Separate regression models were developed for 
intended medical treatment versus PCI, medical treatment versus CABG, 
and CABG versus PCI. All variables entered the multivariable stage, 
irrespective of the results of univariable analyses. The final multivariable 
model was then constructed by backward deletion of the least significant 
characteristics, while applying P=0.05 as the threshold of significance. 
The performance of the multivariable models was studied with respect to 
discrimination and calibration. Discrimination refers to the ability to 
distinguish patient subgoups (intended medical treatment versus PCI; 
intended medical treatment versus CABG; intended CABG versus PCI) by 
using the model. It was quantified by a measure of concordance, the c-
statistic. For binary outcomes the c-statistic is identical to the area under 
the receiver operating characteristic curve. The c-statistic lies between 0.5 
and 1, and is better if closer to 1 [14]. Calibration refers to whether the 
predicted frequencies (by using the model) of patients with a phycisian’s 
preference for a specific treatment modality agree with the observed 
frequencies. Calibration was measured with the Hosmer-Lemeshow 
goodness-of-fit test [15,16]. 
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Table 1: Clinical characteristics of the study population.
 All Intended treatment  P 
  Medical PCI  CABG   
No. of patients 2936 690  1503   743    
Demographics 
Age, years 64 (56-71) 64 (56-71) 63 (54-70)  66 (57-72) ‡ 
Men 77 75 76  80  § 
Risk factors, medical history and medication at admission 
Current smoking 21 17 23  21  § 
Diabetes mellitus (patients using 
  insulin  or oral antidiabetic drugs) 20 22 19  21   
Hypercholesterolemia 69 67 71  66  § 
Hypertension 61 64 60  61   
PCI 24 27 28  12  ‡ 
CABG 13 24 12    4  ‡ 
Myocardial infarction 43 49 41  40  † 
Peripheral vascular disease 13 13 11  17  ‡ 
Cerebro-vascular disease   8   8   6  10  § 
Renal insufficiency   3   5   4    2  § 
Use of beta-blockers, calcium  
  antagonists, or nitrates       † 
    None 11 13 10  11   
    Mono 36 40 37  32   
    Double  41 37 42  45   
    Triple 11 10 12  12   
Presentation 
Concomitant valvular heart disease   7   8   4  13  ‡ 
NYHA symptomatic (heart failure) class       ‡ 
    No heart failure 84 80 89  80   
    I or II 10 13   8  13   
    III or IV   5   8   3    7   
CCS angina class       ‡ 
    I 15 24 14  10   
    II 48 49 50  42   
    III 32 25 31  41   
    IV   5   2   5    6   
Size of the myocardium at risk *       ‡ 
    Small 28 39 29  15   
    Intermediate  53 44 54  58   
    Large 19 16 17  27   




Table 1: continued All Intended treatment  P 
  Medical PCI  CABG   
Left ventricular function #       ‡ 
    Normal (LVEF >50%) 66 59 71  62   
    Mild impairment (LVEF 40-50%) 23 23 22  26   
    Moderate impairment (LVEF 30-40%)   7 10   5    9   
    Severe impairment (LVEF <30%)   4   8   2    3   
Continuous data (age, EuroSCORE) are presented as median values (25th - 75th percentile); 
dichotomous data are presented as percentages. 
P-values: § <0.05; † <0.01; ‡ <0.001. 
* Qualitative estimate based on non-invasive diagnostics as described in the ACC/AHA 
guidelines [10]. 
¶ European System for Cardiac Operative Risk Evaluation, which is a score developed to 
quantify the risk of perioperative mortality in patients scheduled for cardiac surgery [22]. 
# Based on quantitative or qualitative measurements. 
Results
Patients and intended treatment 
The intended treatment was not recorded in 70 (2.3%) patients, leaving 
2936 patients suitable for analysis. Medical therapy was intended in 690 
(24%), PCI in 1503 (51%), and CABG in the remaining 743 (25%) patients 
respectively. Eighty-six percent of patients who were selected for coronary 
revascularization underwent this procedure within one year after initial 
coronary angiography. Twelve percent of patients undergoing PCI were 
treated for in-stent restenosis or restenosis after a prior non-stent 
procedure. In 15% of patients undergoing CABG, coronary surgery was 
combined with valve repair or replacement. 
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Table 2: Angiographical characteristics of the study population.
    
 All Intended treatment P 
Medical PCI CABG  
No. of patients 2936 690  1503  743   
Mitral insufficiency potentially  
requiring surgery 
14  16 11 17 ‡ 
Diseased arteries      
   Left Anterior Descending 73  69   67 88 ‡
   Proximal Left Anterior Descending 33  26 26 52 ‡
   Left Circumflex 59  58 51 78 ‡
   Right Coronary Artery 64 64 56 80 ‡
   Left main   9    8   4 21 ‡
    
Number of diseased arteries    ‡ 
   1 34  40 44   8 
   2 30  26 35 21 
   3 27  25 17 50 
   LM   9    8   4 21 
Number of diseased segments      ‡
   1 29  34 38   8 
   2 23  21 28 15 
   3 18  17 16 21 
t4 30  28 18 57 
Total occlusions      ‡
   0 59  46 69 51 
   1 26  31 21 31 
   2   9  13   6 12 
t3   6  11   4   6 
Type C lesions      ‡
   0 56  48 63 48 
   1 23  24 23 22 
   2 11  14   8 15 
t3 11  14   7 14 
Lesions suitable for PCI      ‡
   0 28  56   6 46 
   1 37  22 53 16 
   2 20  12 26 15 
t3 16  10 15 23 
       
      




Table 2: continued All  Intended treatment P
   Medical PCI CABG  
Lesions suitable for CABG      ‡
   0 24  41 26   4 
   1 26  21 37   8 
   2 17  13 20 16 
t3 33  24 17 72 
Grafts with >50% diameter stenosis *      ‡
   0 39  50 30 27  
   1 30  28 34 27 
t2 31  22 36 46 
Data represent percentages. P-values: § <0.05; † <0.01; ‡ <0.001. 
* In patients with a history of prior CABG only. 
Clinical and angiographical characteristics 
The median age of the study population was 64 years, and 77% were men. 
Twenty percent of patients had diabetes. A history of prior PCI was 
reported in 24% of patients and a prior CABG in 13%. Most patients had 
mild to moderate anginal complaints and an intermediate risk profile. A 
moderately or severely impaired left ventricular function was observed in 
11%. Thirty-four percent of patients had single vessel disease, 57% had 
multivessel disease, and 9% had left main disease. 
Important differences in relevant clinical (table 1) and angiographic (table 2) 
baseline characteristics were observed according to intended treatment. 
Patients in whom the physician preferred medical therapy more often had a 
history of coronary revascularization or a history of myocardial infarction 
than the remaining patients. Their anginal complaints were relatively mild, 
but they more often had symptomatic heart failure. Patients scheduled for 
medical therapy had a small area of jeopardized myocardium, a high 
number of total occlusions and type C lesions, and a low number of lesions 
suitable for revascularization. 
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Table 3: Association between patient characteristics and the phycisian’s preference for PCI 
versus medical treatment, CABG versus medical treatment, and CABG versus PCI. 
 Intended treatment 
PCI versus medical CABG versus medical CABG versus PCI 
Odds ratio 
(95% CI) § 
F2 Odds ratio 
(95% CI) † 
F2 Odds ratio 
(95% CI) ‡  
F2
Age, year          
   <60    1      
   60-70    0.62 (0.41, 0.94)   5     
t70    0.42 (0.25, 0.69) 12     
Male gender 1.4 (1.1, 1.8)   5  1.6 (1.1, 2.3)   6     
         
Hypercholesterolemia       0.62 (0.45, 0.85)  9 
         
Prior PCI    0.65 (0.43, 0.99)   4  0.63 (0.43, 0.93)  5 
Prior CABG          
    No 1   1   1   
    Yes, no diseased grafts 0.43 (0.27, 0.70) 11  0.02 (0.01, 0.05) 66  0.07 (0.02, 0.22)  21 
    Yes, t1 diseased graft 1.5 (1.0, 2.4)   3  0.04 (0.02, 0.07) 86  0.02 (0.01, 0.04)  88 
Prior myocardial infarction    0.75 (0.54, 1.0)   3     
         
Renal insufficiency    0.28 (0.12, 0.66)   9  0.21(0.08, 0.53)  11 
Concomitant valvular 
    heart disease 
   4.8 (2.7, 8.4) 30  5.9 (3.7, 9.9)  44 
         
NYHA symptomatic  
   (heart failure) class 
         
    No heart failure    1      
    I or II    1.0 (0.62, 1.6)   0     
    III or IV    0.46 (0.25, 0.84)   6     
         
CCS angina class          
    I 1   1      
    II 1.8 (1.3, 2.5) 13  1.6 (1.0, 2.6)   4     
    III 1.8 (1.3, 2.6) 11  2.4 (1.4, 3.9) 11     
    IV 6.2 (2.7, 14) 19  7.1 (2.5, 20) 13     
         
Non-invasive risk 
stratification 
         
    Low 1   1      
    Intermediate  2.0 (1.6, 2.7) 27  3.3 (2.2, 4.9) 35     
    High 2.4 (1.6, 3.6) 18  3.4 (2.0, 5.7) 20     
EuroSCORE t3 0.71 (0.54, 0.93)   6  2.1 (1.3, 3.4) 10  2.0 (1.5, 2.7)  19 
         




Table 3: continued Intended treatment 
PCI versus medical CABG versus medical CABG versus PCI 
Odds ratio 
(95% CI) § 
F2 Odds ratio 
(95% CI) † 
F2 Odds ratio 
(95% CI) ‡ 
F2
Left ventricular function          
   Normal (LVEF >50%) 1 1     
   Mild impairment  
   (LVEF 40-50%) 
1.0 (0.79, 1.3)   0  0.75 (0.52, 1.1)   3     
   Moderate impairment  
    (LVEF 30-40%) 
0.38 (0.24, 0.61)  16  0.49 (0.27, 0.87)   6 
    
   Severe impairment  
   (LVEF <30%) 
0.27 (0.14, 0.52)  15  0.18 (0.08, 0.42)  16     
       
Proximal left anterior
descending disease 
   2.2 (1.6, 3.1)  22  1.9 (1.4, 2.6) 17
Left main disease    6.6 (3.4, 12)  34  12 (6.3, 22)  60 
          
Number of diseased arteries          
   1    1   1   
    2    2.1 (1.2, 3.5)   8  1.4 (0.85, 2.2)  2 
    3    3.9 (2.2, 6.8)  23  5.4 (3.2, 8.9)  43 
Total occlusions          
    0 1      1   
    1 0.69 (0.52, 0.91)   7     1.3 (0.93, 1.8)  2 
    2 0.56 (0.36, 0.87)   7     1.1 (0.67, 1.9)  0 
    t3 1.0 (0.60, 1.8)   0     0.42 (0.21, 0.87)  6 
Type C lesions          
    0    1      
    1    0.87 (0.59, 1.3)   0     
    2    0.73 (0.45, 1.2)   2     
    t3    0.40 (0.24, 0.66)  12     
Lesions suitable for PCI          
    0 1   1   1   
    1 28 (20, 41) 308  0.55 (0.36, 0.85)   7  0.03 (0.02, 0.05)  150 
    2 35 (22, 56) 232  0.46 (0.28, 0.75)  10  0.01 (0.01, 0.02)  185 
t3 41 (24, 69) 189  0.40 (0.24, 0.66)  13  0.01 (0.01, 0.02)  185 
Lesions suitable for CABG          
    0 1   1   1   
    1 0.74 (0.51, 1.1)   3  5.1 (2.8, 9.4)  27  4.7 (2.3, 9.4)  19 
    2 0.52 (0.33, 0.80)   9  13 (6.9, 23)  67  27 (13, 56)  77 
    t3 0.26 (0.17, 0.41)  34  36 (20, 66) 136  113 (53, 239)  152 
Odds ratios are adjusted for all variables that remained significant (p<0.05) in multivariable analysis. 
F2 represents the contribution of the variable at hand in the final multivariable model. 
§ odds ratio >1: increased preference for PCI rather than medical treatment. 
† odds ratio >1: increased preference for CABG rather than medical treatment. 
‡ odds ratio >1: increased preference for CABG rather than PCI. 
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Patients scheduled for PCI were younger, and less often had congestive 
heart failure than the remaining patients. Their anginal complaints were 
usually moderate, whereas only a limited number of diseased segments 
was observed. The number of total occlusions and type C lesions was low. 
As compared to patients scheduled for medical treatment, patients 
scheduled for PCI less often had a history of CABG or myocardial infartion. 
As compared to patients scheduled for CABG, they more often had a 
history of CABG, but less often had proximal LAD or left main disease. 
Patients in whom the physician preferred CABG were older, more often 
men, and more often had peripheral vascular disease, cerebro-vascular 
disease, and valvular heart disease than the remaining patients. They often 
had severe anginal symptoms, a large area of myocardium at risk and 
extensive vessel disease. The number of lesions suitable for PCI was low. 
Determinants of intended revascularization versus medical treatment 
The number of lesions suitable for PCI was the most important determinant 
of intended PCI versus medical treatment: a PCI was 28 times more likely 
in patients with at least one lesion suitable for such approach (table 3). The 
severity of the anginal symptoms, the amount of jeopardized myocardium 
and left ventricular function were also important determinants of the choice 
for PCI versus medical treatment. Patients in CCS anginal class II to IV 
were 1.8 to 6.2 times more likely to undergo PCI than those in class I. 
Patients with an intermediate to large amount of myocardium at risk were 
2.0 to 2.4 times more likely to undergo PCI than those with a small amount. 
In contrast, patients with moderately to severely impaired left ventricular 
function were 2.6 to 3.7 times less likely to be scheduled for PCI (odds ratio 




The number of lesions suitable for CABG was the most important 
determinant of intended CABG versus medical treatment: a CABG was 5.1 
to 36 times more likely in patients with one to three or more lesions suitable 
for the surgical approach (table 3). The severity of the anginal symptoms, 
the amount of jeopardized myocardium and left ventricular function were 
also important determinants of the choice for CABG versus medical 
treatment. However, whether or not a CABG has been performed in the 
past was a more decisive factor: patients with a history of CABG were 25 to 
50 less likely to be scheduled for CABG. 
Determinants of intended CABG versus PCI
In patients selected for PCI or CABG, the number of lesions suitable for 
each other technique was the most dominating factor for the final treatment 
choice (table 3). A history of CABG, the presence of left main disease, and 
the presence of valvular heart disease were also important determinants of 
the phycisians preference for either CABG or PCI. Diabetes and left 
ventricular function were not associated with the phycisians choice in this 
respect.
Performance of predictive models 
The discriminative power of the model to separate patients with a 
physician’s preference for medical versus revascularization treatment was 
good. The c-statistics for the PCI versus medical treatment and CABG 
versus medical treatment models were 0.85 and 0.92, respectively. The 
Hosmer-Lemeshow tests for calibration were non-significant (p=0.33 and 
p=0.29, respectively; figure 1, top and middel panel), indicating that the 
models accurately predicted the probability for a patient to be selected for 
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coronary revascularization (PCI or CABG). The discriminative power of the 
model to separate patients with a physician’s preference for CABG versus 
PCI treatment was also excellent (c-statistic 0.95). The Hosmer-Lemeshow 
test for calibration was significant (p<0.001), but the difference between the 
expected and observed probabilities was less than 3% in 8 patient 
subgroups based on the deciles of the probability distribution (figure 1, 
bottom panel). 
Discussion 
In this analysis of patients with stable angina and angiographically 
significant coronary artery disease who enrolled the EHS-CR, 
revascularization was generally preferred in patients with more severe 
anginal complaints, an intermediate to large area of myocardium at risk, 
and a preserved left ventricular function, who had not undergone prior 
coronary revascularization, provided lesions were suitable for treatment. 
Coronary surgery was preferred over PCI in patients with multivessel or left 
main disease, as well as in those with concomitant valvular heart disease, 
provided a sufficient number of lesions were suitable for CABG. 
_________
Figure 1 (opposite page): Expected versus observed proportions of patients with 
a physician’s preference for specific treatment within deciles of expected 
proportions, which are based on multivariable logistic regression models. Top 
panel: Expected proportion of patients with a phycisian’s preference for PCI rather 
than medical treatment. Middle panel: Expected proportion of patients with a 
phycisian’s preference for CABG rather than medical treatment. Bottom panel: 
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To a large extent, these choices are coherent with the 1999 and 2002 
guidelines. There were, however, some intriguing variations between the 
guidelines and the routine practice that is reflected in this survey. Impaired 
left ventricular function was associated with an increased preference for 
medical treatment. This contrasts with guidelines, which recommend 
coronary revascularization for most patients with multivessel disease, 
especially those with abnormal left ventricular function [4]. Indeed, 
randomized trials comparing CABG with medical treatment in multivessel 
disease demonstrated a significant improvement of symptoms, as well as a 
significant mortality reduction during long-term follow-up in favor of 
revascularization treatment, regardless left ventricular function [11]. There 
are only a few randomized trials comparing PCI versus medical treatment, 
but guidelines speculate that patients with an intermediate to large 
myocardium at risk (such as those with two-vessel disease and a proximal 
LAD lesion) will profit as much from PTCA as CABG. The rationale behind 
the deviation from the guidelines that we observed is not entirely clear. In 
fact, the interpretation of our data may be hampered by the heterogeneous 
nature of the medically treated patients. In 45% of patients selected for 
medical treatment, phycisians reported a low-risk natural history as their 
main motivation behind their choice (table 4). At the other hand, in 16% of 
patients, medical treatment was chosen because of a suspected high risk 
of peri-operative complications. 
Patients with a prior history of CABG were much more often selected for 
medical treatment, independent of the severity of anginal symptoms, the 
extent of coronary disease, and the number of lesions suitable for PCI or 
CABG. Clinical trials comparing re-CABG versus medical treatment in 




fact that physicians have been educated with the principle ‘primum non 
nocere’ (“first do no harm”, “better safe than sorry”), may therefore partly 
explain our findings. 
It is interesting that diabetes was not associated with more often preference 
for CABG [17]. Possibly, since large-scale randomized trials are lacking, it 
is still unclear whether optimal medical management or revascularization 
should be preferred in the general population of patients with stable angina 
and diabetes. The ongoing BARI 2D trial, in which diabetic patients will be 
randomly allocated to aggressive medical management, targeting at 
optimal glycemic and metabolic control, or revascularization, may help to 
solve this ‘burgeoning dilemma’, as the investigators call it [18]. 
Limitations 
Our study has several limitations, which should be acknowledged. First, the 
EHS surveys were conducted mainly in hospital settings with liberal access 
to coronary revascularization facilities. It is known that the availability of 
specific medical resources, including coronary revascularization, decreases 
the threshold for its use [19]. Second, patients were only enrolled the EHS-
Table 4: Reasons for choosing medical treatment only.
Reason (not exclusive)  Percentage of patients 
General condition of the patient not suitable for PCI  13 
General condition of the patient not suitable for 
CABG  13 
Low-risk natural history  45 
Very high-risk procedure  16 
Cardiac contra-indication    6 
Vessels not suitable for PCI or CABG  49 
Patient refused PCI    4 
Patient refused CABG    9 
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CR once the presence of coronary disease had been established by 
angiography. Obviously, there are many patients with stable angina without 
recent documentation of the coronary anatomy, who were not studied. 
Third, no Core Lab analysis was performed of the qualifying coronary 
angiogram. Consequently, detailed anatomic information that may have 
influenced treatment decisions was lacking. Finally, the present data have 
been acquired prior to clinical availability of drug-eluting stents [20,21]. To 
which extent the availability of these devices will introduce a change in 
practice and treatment strategy will be examined in a new survey. 
Therefore the current results will serve as a benchmark for the evaluation of 
the impact of drug-eluting stents on the practice of revascularization. 
Conclusions
The EHS-CR learned that treatment decisions in patients with stable CAD 
are largely in agreement with current guidelines. Most important deviations 
between guideline recommendations and clinical practice patterns were 
seen in patients with extensive coronary disease, impaired left ventricular 
function and those with diabetes. The EHS-CR also revealed that treatment 
decisions in patients with stable CAD are determined by multiple factors. 
Interestingly, several of these factors were exclusion criteria in clinical trials 
that have been conducted in these patients, including prior 
revascularization, left main disease, renal failure and heart failure. Thus, in 
order to improve evidence-based medicine, guidelines would need to 
account for this and incorporate specific recommendations regarding the 
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Objective: To evaluate whether in stable angina, preference for coronary 
revascularization by either percutaneous coronary intervention (PCI) or 
coronary bypass surgery (CABG) is influenced by diabetic status and 
whether this has prognostic implications. 
Research Design and Methods: 2928 consecutive patients with stable 
angina who were enrolled in the prospective Euro Heart Survey on 
Coronary Revascularization were studied. Multivariable analyses were 
applied to evaluate the relation between diabetes, treatment decision and 
one-year outcome. 
Results: Diabetes was documented in 587 patients (20%), who had more 
extensive coronary disease. Revascularization was intended in 74% of 
patients with diabetes and in 77% of those without diabetes. In patients 
selected for revascularization, CABG was intended in 35% of diabetic and 
in 33% of non-diabetic patients. Multivariable analyses did not change 
these findings, but in some subgroups diabetes influenced treatment 
decisions. For example, diabetics with mild heart failure had more often 
intended revascularization (91%) than those without diabetes (67%, 
p<0.001). Treatment decisions in patients with more extensive (left main, 
multivessel, or proximal LAD) disease were not influenced by diabetic 
status. Diabetes was not associated with an increased incidence of all-
cause death, non-fatal CVA or non-fatal MI at one-year, regardless 
preferred treatment. The incidence of the combined end points was 7.3% in 
diabetic and 6.8% in non-diabetic patients (adjusted hazard ratio 1.0 and 
95%CI 0.7 to 1.4). 
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Conclusion: In stable angina, treatment decisions regarding 
revascularization or the choice for CABG or PCI were not influenced by 
presence of diabetes. Diabetes was not associated with a poor prognosis. 
Introduction
Prevalence of diabetes in the general population is high, particularly in 
North America (7.9%) and in Europe (7.8%) [1]. In patients with established 
coronary artery disease (CAD) the prevalence of diabetes is even higher. In 
the Euro Heart Survey on Diabetes and the Heart 14% of patients with 
stable CAD had newly detected diabetes, whereas around 37% had 
impaired glucose regulation. Furthermore, patients with CAD and diabetes 
may have a worse prognosis [2,3]. 
Whether coronary revascularization in patients with diabetes has 
comparable benefits as in patients without diabetes is not yet clear. There 
is also debate whether coronary artery bypass surgery (CABG) or 
percutaneous coronary intervention (PCI) should be preferred in diabetes 
[4-6]. As a consequence, current treatment guidelines do not provide a firm 
treatment advise for the general diabetic CAD population, although some 
detailed recommendations are given for specific subgroups [7-14]. 
The Euro Heart Survey on Coronary Revascularization (EHS-CR) was 
developed to obtain quantitative information on the adherence to guidelines 
and prognosis in patients undergoing coronary angiography [15]. The EHS-
CR enrolled 3006 consecutive patients with stable CAD, and this well-




systematic analysis of the relation between patient characteristics 
(including diabetes), invasive treatment choices and prognosis. 
Methods
Euro Heart survey of Coronary Revascularization 
The EHS-CR was described in detail elsewhere [15]. Briefly, the survey 
was designed to screen consecutive patients undergoing invasive 
procedures in the catheterisation laboratory. Patients were enrolled if they 
had a diameter stenosis of at least 50% in at least one major epicardial 
coronary artery. Data were collected by dedicated data collecting officers 
and sent to a central database in the European Heart House (Sophia 
Antipolis, France) via the www, using the MacroTM software (InferMed, 
UK). The collected data included demographics, co-morbidity, diagnosis, 
and detailed information regarding diagnostic angiography and treatment 
modalities. Between November 1, 2001 and March 1, 2002 a total of 5767 
patients were enrolled. 
Treatment decisions 
The EHS-CR is a descriptive study, and the survey protocol did not dictate 
any treatment decision. In general, physicians were encouraged to treat 
their patients in conformance with the most recent guidelines. In order to be 
informed of the physicians preferred, intended treatment, the survey 
included the question: “As the treating physician, which treatment option 
would be your first choice? “ 
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According to the reply on this question, patients were classified with a 
physician’s intention for medical treatment, PCI, or CABG. 
Definitions
Since the EHS-CR was a survey of day-to-day clinical practice, it was 
avoided to require additional specific diagnostic tests. In this context, the 
survey protocol did not require specific measurements to verify the 
diagnosis of co-morbidities, including diabetes. For this study, patients with 
diabetes were classified as those who used oral hypoglycaemic agents, 
insulin or the combination. The extent of CAD was estimated by the number 
of diseased arteries and the number of diseased segments [15]. 
Follow-up
Patients were followed for one year after the initial angiography. However, 
because of logistic reasons, 14 of the 130 hospitals (11%) were not able to 
provide long-term follow-up information. Consequently, follow-up duration 
was only 30 days in 8% of patients and 30-300 days in another 13%. The 
median follow-up duration was 356 days (interquartile range: 308-365 
days). Follow-up data included all-cause mortality, cerebro-vascular 
accidents (CVAs), myocardial infarctions (MIs), and repeat 
revascularization procedures. 
Data description and data analysis 
Continuous data are described as median values and corresponding 
quartiles, dichotomous data as counts and percentages. Univariable 




data) and Chi-square or Fisher’s exact tests (dichotomous data) as 
appropriate. 
A number of multivariable logistic regression analyses were applied to 
further evaluate the relation between diabetic status and intended treatment 
(medical versus revascularization; CABG versus PCI in patients with 
intended revascularization), and the extent to which this relation was 
influenced by a range of clinical and angiographic characteristics. 
Therefore, each separate regression model included a diabetic status 
interaction term. If there was statistical evidence that this interaction term 
contributed to the model, it was concluded that the relation between 
diabetes and intended treatment was influenced by that specific 
characteristic. 
As suggested by previous trials [13], we studied the relation between 
diabetic status and intended treatment in three specific patient subgroups in 
more detail: patients with significant left main disease; patients with 3-
vessel disease, combined with those with 2-vessel disease and a 
significant lesion in the proximal LAD; and patients with 2-vessel disease 
not involving the proximal LAD, combined with those with 1-vessel disease. 
Kaplan-Meier survival analyses, as well as univariable and multivariable 
Cox’ proportional hazard regression were applied to study patient outcome 
at one-year follow-up. Since the number of outcome events was limited, in 
multivariable analyses we only adjusted for the EuroSCORE [16]. We 
report adjusted hazard ratios and corresponding 95% confidence intervals 
(CI).
All statistical tests were 2-sided, and significance was stated at the 
classical 0.05 probability level. 
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Table 1: Characteristics of the study population according to diabetic status. 
   







Demographics    
Age, years 64 (57, 71) 64 (55, 71)  
Men 70 78 ‡ 
Medical history and medication at admission    
Prior PCI 25 24  
Prior CABG 15 12  
Prior myocardial infarction 43 43  
Peripheral vascular disease 18 12 ‡ 
Cerebro-vascular disease 10   7 § 
Chronic renal insufficiency   5   3 § 
Use of beta-blockers, calcium antagonists, or nitrates   
 None   9 11  
 Mono 34 37  
 Double  46 40  
 Triple 11 12  
Presentation    
Concomitant valvular heart disease   7   7  
NYHA symptomatic (heart failure) class    
 I or II   9 10  
 III or IV   7   5  
CCS angina class    
 I 14 16  
 II 50 47  
 III 31 32  
 IV   5   5  
Size of the myocardium at risk *   ‡ 
 small 23 29  
 intermediate 53 53  
 large 24 18  
EuroSCORE ¶   4 (2, 5)   3 (2, 5) ‡ 
Left ventricular function #   † 
 mild impairment (LVEF 40-50%) 26 22  
 moderate impairment (LVEF 30-40%)   9   7  
 severe impairment (LVEF <30%)   4   4  
    
Angiographic characteristics    
Mitral insufficiency potentially requiring surgery 13 14  











Number of diseased arteries   ‡ 
 1 26 36  
 2 27 30  
 3 38 25  
 left main disease   9   9  
Number of diseased segments   ‡ 
 1 22 31  
 2 19 24  
 3 20 17  
t4 38 28  
Grafts with >50% diameter stenosis Œ 60 61  
   
Continuous data (age, EuroSCORE) are presented as median values (25th - 75th percentile); 
dichotomous data are presented as percentages; P values: § <0.05; † <0.01; ‡ <0.001. 
* Qualitative estimate based on non-invasive diagnostics as described in the ACC/AHA 
guidelines [10]. 
¶ European System for Cardiac Operative Risk Evaluation, which is a score developed to quantify 
the risk of perioperative mortality in patients scheduled for cardiac surgery [16]. 
# Based on quantitative or qualitative measurements. 
Œ In patients with a history of prior CABG only. 
Results
Patient characteristics 
A total of 3006 patients were diagnosed with stable angina. Complete data 
on diabetic status and intended treatment was available in 2928 (97%) 
patients, who compose our study population. A total of 587 (20%) patients 
had diabetes. 
 There were important differences in clinical and angiographic baseline 
characteristics between patients with and without diabetes (table 1). 
Patients with diabetes were more often women, and had a higher 
prevalence of chronic renal insufficiency, peripheral vascular disease and 
cerebro-vascular disease. The size of the myocardium at risk was 
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significantly increased in diabetics, as was the Euro-SCORE and the 
number of diseased vessels and segments. Moreover, patients with 
diabetes more often had impaired left ventricular function than those 
without diabetes. 
Univariable analyses 
In patients with diabetes, a PCI was intended in 282 (48%) patients and 
CABG in 155 (26%) patients, compared to 1217 (52%) and 586 (25%) in 
patients without diabetes respectively. There were, however, some specific 
patient subgroups in which the presence of diabetes seemed to influence 
choice of treatment (table 2). The presence of diabetes was associated with 
an increased physician’s preference for medical treatment in women, in 
patients without heart failure, in those with mitral valve insufficiency, and in 
patients with 4 or more diseased segments. In contrast, diabetes was 
associated with an increased preference for revascularization in patients 
with previous PCI, and those with mild heart failure. In the diabetics, an 
increased physician’s preference for CABG rather than PCI was observed 
in patients below the age of 60 years, in women, in patients with previous 
PCI or extensive anti-anginal medication, and in those with a Euro-SCORE 
<3 points. An increased physician’s preference for intervention by PCI 
rather than CABG was observed in diabetic patients with a large area of 
jeopardised myocardium. 
The extent of CAD was strongly associated with the physician’s preference 
for revascularization (table 2). Diabetes did not influence this association. 
Among patients selected for revascularization, CABG was preferred in 





Table 2: Intended invasive versus non-invasive treatment, and intended CABG versus PCI 
according to diabetic status in relation to clinical baseline and angiographic characteristics. 






intended CABG, in those 
with intended 
revascularization 
   Diabetes No 
diabetes
P Diabetes  No 
diabetes
 P 
All  2928 74 77   35  33   
Age <60 yr 1165 77 79   34  26  § 
 60-69 yr   957 74 75   32  37   
t70 yr   806 72 77   42  38   
Sex women   684 68 77 §  35  27  § 
 men 2242 77 77   36  34   
Prior PCI no 2218 72 79 †  43  37  § 
 yes   697 81 71 §  15  17   
            
Prior CABG no 2548 77 80   39  34   
 yes   366 59 53   10  13   
            
no 1673 76 80   35  33   Prior myocardial  
infarction yes 1240 73 73   36  31   
            
no 2535 74 77   33  31   Peripheral vascular  
disease yes   376 75 76   48  41   
            
no 2685 75 77   34  32   Cerebrovascular  
disease yes   225 67 78   53  41   
            
no 2822 75 77   36  33   Chronic renal 
insufficiency yes   102 60 72   22  23   
            
none   314 64 73   32  37   
mono 1060 74 74   34  29   
double 1209 76 80   34  35   
Use of betablockers, 
calciumantagonists,  
nitrates prior to inclusion 
triple   332 77 80   47  32  § 
            
no 2717 75 77   34  30   Concomitant valvular 
heart disease yes   209 63 77   62  62   
            
no heart 
failure 
2469 74 79 §  33  30   
I or II   299 91 67 ‡  47  46   
NYHA symptomatic  
(heart failure) class 
III or IV   159 60 67   48  53   
            
I   437 69 61   29  26   
II 1353 72 77   33  29   
III   903 79 82   42  40   
CCS angina class 
IV   131 85 92   35  39   
Table 2 continues on page 136 
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intended CABG, in those 
with intended 
revascularization 
    Diabetes No 
diabetes
P Diabetes  No 
diabetes
 P 
small   707 64 65   18  20  
Inter-
mediate
1324 75 80   40  31  
Size of the myocardium  
at risk
large   481 80 78   32  46  § 
            
<3 * 1129 80 82   32  23  § EuroSCORE 
t3 1760 72 74   37  38   
            
>50% 1694 75 80 §  34  31   
41-50%   597 77 76   45  38   
31-40%   184 71 64   43  52   
Left ventricular ejection 
fraction
d30%     98 57 51   23  53   
Mitral valve insufficiency no 2409 74 78 §  35  31   
 yes   392 76 72   44  44   
Prioximal LAD disease no 1973 72 75   25  24   
 yes   955 79 82   53  48   
1   987 72 73     8    8   
2   863 77 80   18  24   
3   798 74 79   59  60   
Number of diseased 
arteries
Left Main   272 75 80   67  74   
1   861 74 73     7  10   
2   667 78 79   18  21   
3   512 74 78   46  37   
Number of diseased 
segments
>3   888 73 80 §  55  62   
0   807 49 53   84  79   
1 1073 85 86   14  13   
2   590 85 86   27  20   
Number of diseased 
segments suitable 
for PCI 
>2   458 85 85   40  46   
0   701 57 60     5    8   
1   755 83 80   10  10   
2   511 76 83   28  28   
Number of diseased 
segments suitable 
for CABG 
>2   961 81 84   67  67   
0   144 44 41     7  13   
1   110 62 57     6  10   
Grafts with > 50% 
diameter stenosis 
>2   112 76 66   16  16   
            





After multivariable adjustment for a range of potential cofounders (table 3), 
the odds ratio for the relation between diabetic status and preferred 
revascularization versus medical treatment was 0.91 (95% CI 0.70 to 1.17).  
Thus, the treating physicians did not have a differential preference for either 
medical treatment or coronary revascularization in relation to diabetic 
status. There was also no preference for either CABG or PCI in relation to 
diabetic status, with the adjusted odds ratio 0.92 (95% CI 0.63 to 1.3). 
However, diabetes significantly influenced treatment decisions in several 
subgroups according to age, previous PCI, heart-failure, concomitant 
valvular disease and Euro-Score. For example, the presence of diabetes 
was associated with an increased preference for coronary revascularization 
in patients with mild heart failure (NYHA class I or II). Furthermore, 
diabetes was associated with an increased preference for CABG rather 
than PCI in patients below the age of 60 years, but associated with an 
increased preference for PCI in elderly patients. 
Outcome after one-year 
The incidence of the composite endpoint of all-cause death, non-fatal CVA 
or non-fatal MI at one-year follow-up was 7.3% in patients with diabetes 
and 6.8% in patients without diabetes (adjusted hazard ratio 1.0 and 95%CI 
0.7 to 1.4). Patients with more extensive disease had a higher incidence of 
death, CVA or MI at one-year follow-up than those with less extensive 
disease (figure 1, table 3). However, importantly, in the subgroups 
according to the extent of CAD there were no significant differences in the 
incidence of this composite endpoint between patients with and without 
diabetes.

































































































































































































































Table 3: Multivariably adjusted association between treated diabetes and intended treatment 
according to patient characteristics with significant interaction. 
      
   Intended revascularization 
(versus medical treatment) 
 Intended CABG (versus PCI) § 
All   Adjusted odds 
ratio (95% CI)* 
 P-value for 
homogenity
 Adjusted odds 
ratio (95% CI)* 
 P-value for 
homogeneity 
All   0.91 (0.70, 1.17)    0.92 (0.63, 1.3)   
Age <60 yr      1.6   (0.88, 2.9)  reference 
 60-69 yr      0.53 (0.22, 1.3)  0.004 
t70 yr      0.63 (0.25, 1.5)  0.29 
          
Prior PCI no  0.74  (0.55, 1.0)  reference     
 yes  1.7    (0.93, 3.1)  0.007     
          
no heart 
failure 
 0.77  (0.59, 1.0) reference     
I or II  8.3       (2.8, 25) <0.001     
III or IV  0.63  (0.25, 1.5) 0.85     
          
no     1.0     (0.7, 1.5)  reference Concomitant 
valvular heart 
disease 
yes     0.25 (0.06, 
0.95)
 0.047 
          
<3     2.1     (1.1, 3.7)  reference EuroSCORE
t3     0.55 (0.26, 1.2)  <0.001 
          
* An odds ratio>1 implies that treated diabetes is associated with an increased preference for the 
treatment option in the corresponding column, whereas an odds ratio <1 implies that treated diabetes is 
associated with an increased preference for the alternative. Odds ratios are adjusted for all variables 
that are listed in tables 2 and 3, as appropriate. 
§ The analysis is limited to patients with intended coronary revascularization. 
Concerning the relation between diabetic status, treatment choice and 
outcome, because of small numbers, patients with left main disease or 3-
vessel disease were considered as one group. Regardless of the extent of 
the disease, patients selected for PCI had a lower incidence of major 
adverse cardiovascular or cerebro-vascular events at 1-year follow-up than 
those selected for medical treatment or CABG (table 4), but again we 
observed no difference in the relation between intended treatment and 
outcome according to diabetic status. 
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Table 4: Incidence of adverse cardiac complications at 1 year follow-up according to the 
extent of coronary disease, intended treatment and diabetic status. 
        
 Intended 
treatment












or (re)PCI at 




        
Any Yes 587   7.3 1.0 (0.7, 1.4) 15.9 1.0 (0.8, 1.3) 
 No 2341   6.8 1 13.8 1 
       
Medical Yes   150   6.7 0.9 (0.5, 1.7) í í
 No   538   7.6 1 í í
       
PCI Yes   282   5.3 1.0 (0.6, 1.8) 16.8 1.1 (0.8, 1.6) 
 No 1217   4.9 1 14.8 1 
       
CABG Yes   155 12.0 1.1 (0.6, 1.9) 12.8 1.0 (0.6, 1.8) 
All patients 
 No   586 10.2 1 11.7 1 
        
Any Yes   317 10.2 1.1 (0.7, 1.7) 18.5 1.2 (0.8, 1.7) 
 No 1005   8.5 1 14.4 1 
       
Medical Yes     77   9.9 0.8 (0.3, 1.9) í í
 No   202 10.2 1 í í
       
PCI Yes   108   8.3 1.3 (0.5, 2.9) 26.6 1.4 (0.9, 2.2) 
 No   331   6.2 1 18.9 1 
       
CABG Yes   132 12.1 1.2 (0.6, 2.3) 11.6 1.0  (0.6, 1.9) 
Left main 
OR
3 vessel disease  
OR
2 vessel disease  
and proximal LAD 
 No   472   9.3 1 11.1 1 
        
Any Yes   268   4.0 0.8 (0.4, 1.5) 12.8 0.8 (0.6, 1.3) 
 No 1330   5.6 1 13.4 1 
       
Medical Yes     73   3.3 1.0 (0.3, 2.9) í í
 No   335   6.0 1 í í
       
PCI Yes   173   3.4 0.8 (0.3, 1.9) 11.9 0.8  (0.5, 1.4) 
 No   881   4.4 1 13.3 1 
       
CABG Yes     22 11.1 0.7 (0.2, 3.1) 19.2 1.0 (0.3, 3.4) 
1 vessel disease  
OR
2 vessel disease, 
but no proximal 
LAD
 No   114 13.5 1 14.2 1 
§ Kaplan-Meier estimate. 
† Hazard ratio’s are adjusted for differences in EuroSCORE between groups. 





This analysis revealed that in stable angina subsequent treatment 
decisions regarding revascularization (and the choice for either CABG or 
PCI) were not influenced by the presence of diabetes. Importantly, diabetic 
patients with left main disease, proximal LAD disease, or more extensive, 
multivessel disease were not more likely to undergo coronary 
revascularization (or CABG) than their non-diabetic counterparts. Diabetes 
was also not associated with a poor prognosis. 
Previous (1999) and current (2002) guidelines recommend CABG rather 
than PCI in patients with diabetes and multivessel disease [10,11]. This 
treatment advise is mainly based on post-hoc analyses from randomised 
trials that were conducted before the use of stents and glycoprotein (GP) 
IIb/IIIa inhibitors. In the BARI trial, patients with treated diabetes who were 
randomised to CABG had significant better survival after 7-year follow-up 
than those randomised to balloon angioplasty [4]. To some extent, this 
finding was confirmed by a meta-analysis of 13 randomised trials of CABG 
versus balloon angioplasty (including BARI), which demonstrated improved 
survival in favour of CABG at 4-year follow-up, but no longer at 6.5-year 
follow-up [17]. 
How can we understand the discrepancy between guidelines 
recommendations and the clinical practice patterns that we observed? 
Possibly, those involved in the care of patients with stable angina are not 
convinced that patients with diabetes should be treated differently than 
those without diabetes, especially since large-scale randomised trials are 
lacking. The ongoing BARI 2D trial, in which diabetic patients will be 
randomly allocated to aggressive medical management, targeting at 
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optimal glycemic and metabolic control, or revascularization, may help to 
solve this ‘burgeoning dilemma’, as the investigators call it [18]. 
Furthermore, it is well-known that patients enrolled in clinical trials form a 
selected population, particularly in randomised trials comparing PCI and 
CABG [19]. In this respect, observational studies, including the BARI 
registry [5], reported similar outcome after CABG and PCI in patients with 
diabetes and symptomatic coronary disease [6]. 
Another interesting aspect is emphasised by McGuire et al., who evaluated 
the effects of reporting the BARI trial results (which were made public 
together with a ‘clinical alert’) on decision-making [20]. It was reported that 
the rapid advancement of healthcare technology was the major factor of the 
lack of influence of the clinical alert and the BARI trial on current clinical 
practice. More recent randomised trials comparing CABG against stenting 
with liberal use of GP IIb/IIIa inhibitors, which were conducted during 1996-
2000, demonstrating more favourable results in those with diabetes [21],  
may have influenced treatment decisions. 
Probably, antirestenotic, drug-eluting stents (DES) will improve the results 
of PCI relative to CABG in diabetic patients [22,23]. The ongoing CARDia, 
FREEDOM and BARI 2D trials, which enrol patients with coronary disease 
and diabetes, who are randomised to either CABG or PCI with DES and 
modern antiplatelet therapy, including GP IIb/IIIa inhibitors and clopidogrel, 
may shed a vivid light on the PCI-versus-CABG debate. 
In our survey, diabetes was not associated with an increased incidence of 
major adverse cardiac and cerebral events. Especially diabetic patients 
scheduled for PCI had similar prognosis as non-diabetics. It is true that the 
limited number of patients and the short duration of follow-up might have 




be excluded with sufficient certainty. These observations seem to justify the 
position of PCI as a safe treatment for patients with diabetes and stable 
CAD.
Limitations 
This study has several limitations, which need to be addressed. First, The 
EHS-CR was conducted mainly in hospitals with liberal access to coronary 
revascularization facilities. It is known that the availability of specific 
medical resources decreases the threshold for it’s use [24]. Thus, the 
percentage of patients undergoing revascularization, particularly CABG, 
might have been relative high. However, there is no indication that this has 
been differently so in patients with and without diabetes. 
Second, as the EHS-CR is a survey of routine clinical practice, the treating 
physician was not enforced to use specific laboratory tests in order to 
establish the diagnosis ‘diabetes’. Thus, we cannot exclude the possibility 
that misclassification of diabetes had occurred. However, the clinical and 
angiographic characteristics of patients with diabetes corresponded quite 
well with other datasets of diabetics with stable coronary disease [25]. 
Third, no Core Lab analysis was performed of the qualifying coronary 
angiography. Consequently, detailed anatomic information that may have 
influenced treatment decisions was lacking. This is especially relevant for 
the 366 patients with a prior history of CABG. However, sensitivity analyses 
that excluded these patients showed consistent results. 
Conclusions
Diabetes is not among the factors that determine treatment decisions 
regarding revascularization in patients with stable coronary disease. 
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Diabetes was not associated with a worse prognosis, independent of 
invasive treatment preference. In expectation of the results of ongoing 
clinical trials, comparing several medical and more invasive treatment 
strategies, guidelines for the management of CAD patients with diabetes 
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The main objective of the studies presented in this thesis was to provide 
more insight in several aspects of coronary revascularisation, including 
decision-making in daily practice and (long-term) prognostic implications. 
Particular attention was paid to patients with coronary artery disease (CAD) 
who have multivessel disease and patients with diabetes.  
Main findings of the studies 
Chapter 1 provides a general introduction and describes the outline of the 
thesis. Coronary revascularisation by either CABG or PCI are nowadays 
frequently used and widely accepted for the treatment of several clinical 
manifestations of CAD. Although both methods of coronary 
revascularisation have been improved in the past decades, treatment 
decision-making (medical treatment versus revascularisation, PCI versus 
CABG) in individual patients may be difficult, in part because most 
randomised controlled trials have low external validity. 
In chapter 2 current evidence of the prognostic implication of 
revascularisation in patients with Non-ST Elevation Acute Coronary 
Syndrome (NSTE-ACS) is reviewed. Immediate as well as early 
revascularisation may be beneficial in these patients, but has traditionally 
been employed as an ‘ischemia-guided’ strategy. A number of randomised 
trials (including more than 10,000 patients) and observational studies have 
compared routine invasive versus selective invasive strategies. Most 
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randomised trials are limited by a high cross-over rate, whereas 
observational studies are limited by selection bias. Data from registries 
demonstrated benefits with revascularisation, with lower mortality. Results 
from randomised trials are less clear with regard to mortality reduction, 
although long-term survival after hospital discharge may be better after the 
invasive approach. In the randomised trials there was a decreased risk of 
death or MI after the invasive approach (OR 0.88, 95% CI 0.76-1.0). It can 
be concluded that the optimal timing of angiography and subsequent 
revascularisation is still somewhat uncertain, but that angiography and 
revascularisation should be considered in every patient admitted with a 
NSTE-ACS, particularly in those with high-risk characteristics, such as ST 
segment depression >0.1 mV, accelerated angina in the prior 2 months, 
nitrate use in the prior week before admission or elevated troponin. 
The objective of chapter 3 was to evaluate the relationship between the 
completeness of revascularisation by percutaneous coronary intervention 
and the one-year occurrence of adverse cardiac events in patients with 
multivessel disease who were enrolled in the Coronary Angioplastry versus 
Bypass Revascularisation Investigation (CABRI). In CABRI, patients were 
randomised to CABG (n=513) or PCI (n=541). Revascularisation in patients 
randomised to PCI was defined as complete if no lesions with a diameter 
stenosis >50% remained post-procedure. Patients with complete 
revascularisation were distinguished from those with one, two or three or 
more remaining lesions, respectively. Differences in baseline 
characteristics and in the one-year occurrence of death, myocardial 
infarction, (re)CABG and (re)PCI between these subgroups were 
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evaluated. Comparisons were made with patients randomised to CABG. 
Complete revascularisation was obtained in 148 patients randomised to 
PCI (27%). In 147 (27%) cases one lesion remained, while there were 122 
(23%) and 119 (22%) patients with two and three or more remaining 
lesions, respectively. Five (1%) patients could not be classified. The one-
year rates of either death or MI were 9.5%, 5.4%, 8.2% and 12.6% in the 
respective PCI subgroups (P=0.23), and 6.2% in patients randomised to 
CABG (comparison with three or more remaining lesions after PCI: p=0.02) 
The percentages of repeat interventions during one-year follow-up were 
29.7%, 29.3%, 39.3% and 51.3% (p<0.001), much higher than after CABG 
(3.5%; p<0.001). It was concluded that complete revascularisation by PCI 
in multivessel coronary disease did not result in a lower death or MI rate 
compared with incomplete revascularisation. Overall, the patient’s 
prognosis after PCI is similar to CABG, but patients with three or more 
remaining lesions after PCI had a worse prognosis than CABG patients, 
with a higher incidence of the combined endpoint death or MI as well as 
more additional procedures. 
Chapter 4 describes the 6-month clinical outcome of patients with 
multivessel disease enrolled in PURSUIT (Platelet Glycoprotein IIb/IIIa in 
Unstable Angina: Receptor Suppression Using Integrelin Therapy). Patients 
were divided into three groups according to the treatment strategy applied 
during the first 30 days of enrolment. The PCI group was further 
subdivided: patients receiving coronary stents were separated from those in 
whom no stents were used. Mortality after 30 days was 6.7, 3.9, 2.4 and 
4.8% for the medical treatment, PCI (balloon), PCI (stent) and CABG 
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groups, respectively (p value = 0.002). Differences as observed at 30 days 
were still present at 6-month follow-up with 11.1, 5.8, 5.5 and 6.5% 
mortality event rates for the aforementioned groups (p value = 0.002). The 
30-day myocardial infarction (MI) rate was lower among medically than 
non-medically treated patients, with the highest event rate observed in the 
CABG group (27.7%). Approximately half of the MIs in the PCI and CABG 
subgroups occurred within 48 h after the procedure. However, it was 
concluded that the observed differences in clinical outcomes can be 
explained by an imbalance in baseline characteristics and comorbid 
conditions
In chapter 5, long-term survival is studied in unselected patients with 
coronary artery disease who are potential candidates for an invasive 
approach. Data from DUtch inventory of invasive Coronary Atherosclerosis 
Treatments (DUCAT) study were used. All patients with significant coronary 
artery disease who were presented for coronary revascularisation to two 
tertiary centres in 1992 were included. Follow-up data were collected in 
September 2002. A total of 877 patients were included in this analysis. 
Mean age was 62 and the most common clinical diagnosis was chronic 
stable angina (60%). Diabetes was present in 12% of the patients. During 
the follow-up period, a total of 233 patients (27%) died. Predictors of long-
term survival were increasing age, diabetes, peripheral vascular disease 
and a decreased left ventricular function. Compared to medical treated 
patients, those treated with revascularisation (either by PCI or CABG) had 
a decreased long-term mortality (p0.05). Of the patients with PCI 27% had 
died, compared to 24% in those who had CABG and 36% of those who 
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were treated medically. However, after adjusting for differences in baseline 
variables, conservative treatment was no significant predictor of long-term 
mortality. After multivariable analyses, increasing age, decreased left 
ventricular function and diabetes were independent predictors of long-term 
mortality.
The optimal method of coronary revascularisation in diabetic patients 
remains controversial. In chapter 6, it was our aim to evaluate long-term 
outcome of diabetic patients with coronary artery disease in daily practice in 
whom an invasive approach was considered. As in chapter 5, data from the 
DUCAT study were used. A total of 107 patients (12%) had diabetes. 
Patients with diabetes were older and more frequently women. Long-term 
mortality was higher in diabetes than in non-diabetes (36% vs. 25%, 
p=0.01). This association was observed in both medical treated patients 
(65% vs. 31%, p=0.01) and in those treated with percutaneous coronary 
intervention (41% vs. 24%, p=0.02). There was, however, no difference in 
mortality in diabetes versus non-diabetes after CABG (24% vs. 24%, 
p=0.89). Multivariate analysis did not change these findings. It was 
concluded that in patients with coronary artery disease in whom an invasive 
approach is considered, diabetes was associated with a higher long-term 
mortality. After coronary artery bypass grafting, long-term survival may be 
comparable between patients with and without diabetes. 
Determinants of clinical decision-making in patients with stable CAD were 
assessed in chapter 7. The 2936 patients with stable angina pectoris who 
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enrolled the Euro Heart Survey on Coronary Revascularisation (EHS-CR) 
were subject of this analysis. After the diagnosis was confirmed, physicians 
decided upon treatment: only medical management, or combined by 
revascularisation therapy by PCI or CABG. Logistic regression analyses 
were applied to evaluate the relation between baseline characteristics and 
treatment decision: medical treatment versus PCI, medical treatment 
versus CABG and PCI versus CABG. Median age of the patients was 64 
years, 77% were men and 20% had diabetes. Medical therapy was 
intended in 690 (24%), PCI in 1503 (51%), and CABG in the remaining 743 
(25%) patients respectively. Revascularisation was generally preferred in 
patients with more severe anginal complaints, an intermediate to large area 
of myocardium at risk, and a preserved left ventricular function, who had 
not undergone prior coronary revascularisation, provided lesions were 
suitable for treatment. CABG was preferred over PCI in multivessel or left 
main disease, as well as in those with concomitant valvular heart disease, 
provided a sufficient number of lesions were suitable for CABG. In those 
with previous CABG, more often PCI was preferred than re-CABG. 
Diabetes was not associated with more often preference for CABG. 
This analysis of the EHS-CR revealed that treatment decisions in patients 
with stable CAD are determined by multiple factors and in general are in 
agreement with the guidelines. However in patients with diabetes there is 
no preference of CABG over PCI. In patients with previous CABG, PCI is 
the preferred therapy in the group of patients scheduled for 
revascularisation.
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The objective of chapter 8 was to evaluate whether in stable angina, 
preference for coronary revascularisation by either percutaneous coronary 
intervention (PCI) or coronary bypass surgery (CABG) was influenced by 
diabetic status and whether this had prognostic implications. The 2928 
consecutive patients with stable angina who were enrolled in the 
prospective Euro Heart Survey on Coronary Revascularisation were 
studied. Multivariable analyses were applied to evaluate the relation 
between diabetes, treatment decision and one-year outcome. Diabetes was 
documented in 587 patients (20%), who had more extensive coronary 
disease. Revascularisation was intended in 74% of patients with diabetes 
and in 77% of those without diabetes. In patients selected for 
revascularisation, CABG was intended in 35% of diabetic and in 33% of 
non-diabetic patients. Multivariable analyses did not change these findings, 
but in some subgroups the presence of diabetes influenced treatment 
decisions. For example, diabetics with mild heart failure had more often 
intended revascularisation (91%) than those without diabetes (67%, 
p<0.001). Treatment decisions in patients with more extensive (left main, 
multivessel, or proximal LAD) disease were not influenced by diabetic 
status. Diabetes was not associated with an increased incidence of all-
cause death, non-fatal CVA or non-fatal MI at one-year, regardless of the 
preferred treatment. The incidence of the combined end points was 7.3% in 
diabetic and 6.8% in non-diabetic patients (adjusted hazard ratio 1.0 and 
95%CI 0.7 to 1.4). It can be concluded that in stable angina, treatment 
decisions regarding revascularisation or the choice for CABG or PCI were 
not influenced by presence of diabetes. Diabetes was not associated with a 
poor prognosis. 
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Final comments and future directions 
Coronary revascularisation by either PCI or CABG is an important 
treatment option for patients with (symptomatic) coronary artery disease. It 
may relief symptoms and in selected patients improve survival. Although 
both revascularisation techniques have been improved during the past 
decades, one of the challenges for the future is to apply the appropriate 
treatment to the individual patient at the optimal moment in time. Results of 
randomised controlled trials are important for making this decision. 
However, most trials have also several limitations, such as a low external 
validity and short follow-up period. Moreover, most randomised trials in the 
field of revascularisation are not blinded, and results may be influenced by 
crossover. Therefore, these trials should be combined with data from 
observational studies. Because treatment regimens change, the continuous 
evaluation of effects of treatment (on subgroups) in daily practice remains 
mandatory.
The extent of CAD is important in the selection of the mode of 
revascularisation therapy. Completeness of revascularisation may improve 
prognosis. Whether in patients with multivessel disease CABG or PCI 
should be the preferred strategy has to be further assessed in many 
subgroups of patients with CAD, especially in those with diabetes. 
Diabetes is one of the most important co-morbidities in patients with CAD 
and is characterised by a rapidly increasing prevalence in the general 
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population. It is still uncertain whether PCI or CABG should be preferred in 
the majority of patients with diabetes and CAD. Probably, antirestenotic, 
drug-eluting stents (DES) will improve the results of PCI relative to CABG in 
these patients. The ongoing CARDia, FREEDOM and BARI 2D trials, which 
enroll patients with CAD and diabetes, who are randomised to either CABG 
or PCI with DES and modern antiplatelet therapy, including GP IIb/IIIa 
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De studies die worden gepresenteerd in dit proefschrift hebben als 
voornaamste doel om meer inzicht te verschaffen in een aantal aspecten 
van coronaire revascularisatie technieken, waaronder besluitvorming in de 
dagelijkse praktijk en de gevolgen daarvan op de lange termijn. Patiënten 
met meervats coronairlijden of diabetes mellitus hadden onze bijzondere 
belangstelling. 
Belangrijkste bevindingen van de studies 
Hoofdstuk 1 geeft  een algemene inleiding en beschrijft de inhoud van het 
proefschrift. Coronaire revascularisatie door middel van CABG of PCI wordt 
tegenwoordig veelvuldig gebruikt voor de behandeling van verschillende 
klinische uitingen van coronairlijden. Hoewel beide technieken gedurende 
de afgelopen decennia zijn verbeterd, kan het maken van beslissingen bij 
de individuele patiënt  moeilijk zijn, voor een deel omdat de externe 
validiteit van de meeste gerandomiseerde studies laag is. 
In hoofdstuk 2 wordt een overzicht gegeven van de studies en de 
registraties met betrekking tot het effect van coronaire revascularisatie op 
de prognose van patiënten met een niet-ST elevatie myocardinfarct. 
Vroege revascularisatie werd in het verleden vooral aanbevolen op geleide 
van aantoonbare ischemie. Een aantal gerandomiseerde studies, waarin 
meer dan 10.000 patiënten deelnamen, en observationele studies 
vergeleken een routine invasieve benadering met een meer selectieve 
invasieve strategie. De meeste gerandomiseerde studies worden beperkt 
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door een hoog “cross over” percentage, waarbij met name in de selectieve 
groep, patiënten toch een revascularisatie ondergingen. Observationele 
studies worden  beperkt door de mogelijke verstorende invloed van selectie 
bias. Deze observationele studies laten een duidelijk voordeel zien van 
revascularisatie, met lagere sterfte. De resultaten van gerandomiseerde 
studies zijn niet eenduidig ten aanzien van vermindering van sterfte. De 
overleving op langere termijn na ontslag uit het ziekenhuis is mogelijk beter 
na een invasieve aanpak. In de gerandomiseerde studies werd een afname 
van de combinatie van sterfte en infarcten na een invasieve benadering 
gevonden (OR 0,88, 95% CI 0,76-1,0). Er kan worden geconcludeerd dat 
er nog steeds enige onzekerheid bestaat over het optimale tijdstip van 
angiografie en eventuele revascularisatie, maar dat  angiografie en 
mogelijke revascularisatie in principe moet worden overwogen bij iedere 
patiënt die zich met een niet-ST elevatie ACS presenteert, in het bijzonder 
patiënten met hoog-risico karakteristieken zoals ST-segment depressie van 
meer dan 0,1 mV, progressieve angina pectoris in de afgelopen 2 
maanden, nitraat gebruik in de week voorafgaand aan opname of 
verhoogde troponine. 
In hoofdstuk 3 wordt de relatie onderzocht tussen de volledigheid van 
revascularisatie door middel van PCI en het optreden van cardiale 
gebeurtenissen gedurende 1 jaar bij patiënten met meervats-coronairlijden 
die waren geincludeerd in de Coronary Angioplasty versus Bypass 
Revascularisation Investigation (CABRI) studie. In de CABRI studie werden 
patiënten gerandomiseerd naar CABG (n=513) of PCI (n=541). Van 
complete revascularisatie na PCI was sprake indien er na de procedure 
geen afwijkingen over waren met een diameter stenose van >50%. 
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Patiënten met complete revascularisatie werden vergeleken met  patiënten 
met 1, 2 en 3 of meer overgebleven afwijkingen. Verschillen in basale 
kenmerken en het optreden van sterfte, myocardinfarct, (re-) CABG en (re-) 
PCI tussen deze subgroepen werden geëvalueerd. Vergelijkingen werden 
gemaakt met patiënten die naar CABG werden gerandomiseerd. Complete 
revascularisatie werd bereikt in 148 patiënten die naar PCI waren 
gerandomiseerd (27%). Bij 147 patiënten (27%) bleef 1 afwijking over, 
terwijl in respectievelijk 122 (23%) en 119 (22%) patiënten, 2  en 3 of meer 
afwijkingen overbleven. Vijf patiënten (1%) konden niet worden 
geclassificeerd. Het percentage sterfte en/of myocardinfarct gedurende 1 
jaar was respectievelijk 9,5%, 5,4%, 8,2% en 12,6% in de PCI subgroepen 
(P=0,23), en 6,2% in patiënten die werden  gerandomiseerd naar CABG 
(vergelijking met 3 of meer overgebleven afwijkingen na PCI: p=0,02). ) De 
percentages re-interventies gedurende 1 jaar waren 29,7%, 29,3%, 39,3% 
and 51,3% (p<0,001), wat in iedere groep hoger was dan na CABG (3,5%; 
p<0,001). Complete revascularisatie met PCI bij meervatscoronair lijden 
resulteerde niet in een lagere sterfte en/of myocardinfarct in vergelijking 
met incomplete revascularisatie. Over het algemeen is de prognose van de 
patiënten na  PCI vergelijkbaar met CABG. Patiënten met 3 of meer 
overgebleven afwijkingen na  PCI hebben een slechtere prognose dan 
CABG patiënten, door een hogere incidentie van het gecombineerde 
eindpunt dood of infarct en meer aanvullende procedures. 
In hoofdstuk 4 wordt de 6-maanden klinische uitkomst beschreven bij  
patiënten met meervatslijden die werden geincludeerd in de PURSUIT 
(Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression 
Using Integrelin Therapy) studie. Patiënten werden onderverdeeld in 3 
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groepen volgens de toegepaste behandelstrategie gedurende de eerste 30 
dagen na inclusie. De PCI groep werd verder onderverdeeld naar patiënten 
die al dan niet met een coronaire stent werden behandeld. De sterfte na 30 
dagen was respectievelijk 6,7%, 3,9%, 2,4% en 4,8% voor de  
medicamenteuze, PCI (ballon), PCI (stent) en CABG groep (p = 0,002). 
Deze verschillen waren nog steeds aanwezig na 6-maanden met 
respectievelijk 11,1%, 5,8%, 5,5% en 6,5% sterfte (p = 0,002). Het 
optreden van een myocardinfarct binnen 30 dagen was lager bij de 
medicamenteuze in vergelijking met de niet medicamenteus behandelde 
patiënten, waarbij het hoogste percentage werd gevonden in de CABG 
groep (27,7%). Ongeveer de helft van de myocardinfarcten in de PCI en 
CABG subgroepen deed zich voor binnen 48 uur na de procedure. Er werd 
geconcludeerd dat de geobserveerde verschillen in klinische uitkomsten 
mede verklaard kunnen worden door een verschil in basis karakteristieken 
en co-morbiditeit. 
In hoofdstuk 5, werd de lange termijn overleving bestudeerd in een groep 
ongeselecteerde patiënten met coronairlijden die kandidaat waren voor een 
invasieve behandeling. 
Gegevens van de “DUtch inventory of invasive Coronary Atherosclerosis 
Treatments” (DUCAT) studie werden gebruikt. Alle patiënten met significant 
coronairlijden die in aanmerking kwamen voor coronaire revascularisatie in 
twee tertiaire centra in 1992 werden geincludeerd, vervolg gegevens 
werden verzameld in september 2002. In totaal  werden 877 patiënten 
geincludeerd in deze analyse. De gemiddelde leeftijd was 62 jaar, 
chronische stabiele angina pectoris (60%) was de meest gestelde 
diagnose. Twaalf procent van de patiënten had diabetes mellitus. 
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Gedurende het vervolgonderzoek bleken 233 patiënten (27%) te zijn 
overleden. Voorspellers van lange termijn sterfte waren hogere leeftijd, 
diabetes mellitus, perifeer vaatlijden en  verminderde linker ventrikel 
functie. In vergelijking met medicamenteus behandelde patiënten, hadden 
patiënten  behandeld met  revascularisatie (PCI of CABG)  een lagere 
lange termijn sterfte (p0,05). Van de  patiënten die werden behandeld met 
PCI  was 27% overleden, in vergelijking met  24% van de patiënten die een 
CABG hadden ondergaan en 36% van degenen die medicamenteus waren 
behandeld. Na correctie voor verschillen in basale variabelen bleek 
conservatieve therapie echter geen significante voorspeller voor lange 
termijn sterfte. Na multivariate analyse bleken hogere leeftijd, verminderde 
linker ventrikel functie en diabetes mellitus onafhankelijke voorspellers van 
lange termijn sterfte. 
De optimale methode van coronaire revascularisatie bij patiënten met 
diabetes mellitus blijft controversieel. De doelstelling van hoofdstuk 6 was
om de lange termijn uitkomst te evalueren in de dagelijkse praktijk bij 
diabeten met coronairlijden waarbij een invasieve aanpak wordt 
overwogen. Hiervoor werden, evenals in hoofdstuk 5, gegevens gebruikt 
van de DUCAT studie. Van de geincludeerde patiënten hadden 107 
patiënten (12%) diabetes mellitus. Patiënten met diabetes waren ouder en 
vaker vrouw. Lange termijn sterfte was hoger in diabeten dan in niet-
diabeten (36% vs. 25%, p=0,01). Deze associatie werd gevonden in 
medicamenteus behandelde patiënten (65% vs. 31%, p=0,01) en in 
patiënten behandeld met PCI (41% vs. 24%, p=0,02). Er was echter geen 
verschil in sterfte tusen patiënten met of zonder diabetes die waren 
behandeld met CABG (24% vs. 24%, p=0,89). Multivariate analyse 
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veranderde deze resultaten niet. Er werd geconcludeerd dat  diabetes 
geassocieerd was met een hogere lange termijn sterfte bij patiënten met 
coronairlijden bij wie een invasieve aanpak werd overwogen. Bij patiënten 
met diabetes die behandeld worden met CABG lijkt de lange termijn 
overleving echter niet slechter te zijn. 
In hoofdstuk 7 werden factoren die van belang zijn voor klinische 
besluitvorming met betrekking tot revascularisatie bij patiënten met stabiel 
coronairlijden onderzocht. De 2936 patiënten met stabiele angina pectoris, 
geincludeerd in de Euro Heart Survey on Coronary Revascularisation 
(EHS-CR) waren onderwerp van deze analyse. Nadat de diagnose was 
bevestigd werd tot een behandeling overgegaan: uitsluitend 
medicamenteus of gecominbeerd met revascularisatie middels PCI of 
CABG. Teneinde de onafhankelijke relatie te evalueren tussen basale 
karakteristieken en een behandelbeslissing (medicamenteus versus PCI, 
medicamenteus versus CABG en PCI versus CABG), werd logistische 
regressie analyse toegepast. De mediane leeftijd van de patiënten was 64 
jaar, 77% was man en 20% van de patiënten had diabetes mellitus. 
Medicamenteuze therapie was de voorgenomen therapie in 690 (24%), PCI 
in 1503 (51%), en CABG in the overige 743 (25%) patiënten. 
Revascularisatie had de voorkeur bij patiënten met ernstiger angina 
pectoris, een matig tot groot bedreigd deel van het myocard, en een 
behouden linker ventrikel functie en bij patiënten zonder revascularisatie 
therapie in de voorgeschiedenis, mits de afwijkingen geschikt waren voor 
behandeling. Bij patiënten met meervatslijden of hoofdstam vernauwing en 
bij patiënten met bijkomend kleplijden had CABG  de voorkeur boven PCI, 
mits er voldoende afwijkingen geschikt waren voor CABG. Een PCI had  de 
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voorkeur boven re-CABG bij patiënten met een CABG in de 
voorgeschiedenis.
Deze analyse van de EHS-CR toont aan dat behandelbeslissingen bij 
patiënten met stabiel coronairlijden bepaald worden door meerdere 
factoren en globaal in overeenstemming zijn met de richtlijnen. Bij patiënten 
met diabetes mellitus echter, bestaat geen voorkeur voor CABG boven 
PCI. In de groep van patiënten die werden voorgesteld voor 
revascularisatie had PCI  de voorkeur bij patiënten met een CABG in de 
voorgeschiedenis.
In hoofdstuk 8 werd geëvalueerd of bij patiënten met stabiele angina, 
voorkeur voor coronaire revascularisatie middels PCI of CABG beïnvloed 
werd door de aanwezigheid van diabetes mellitus en of dit prognostische 
implicaties had. De 2928 patiënten met stabiele angina die werden 
geincludeerd in de prospectieve Euro Heart Survey on Coronary 
Revascularisation werden bestudeerd. Multivariate analyse werd toegepast 
teneinde de onafhankelijke relatie tussen diabetes mellitus, behandel 
beslissingen  en uitkomst na 1 jaar te evalueren. Diabetes mellitus was 
gedocumenteerd in 587 patiënten (20%). Deze patiënten hadden meer 
uitgebreid coronairlijden. Revascularisatie werd voorgenomen in 74% van 
de patiënten met en in 77% van de patiënen zonder diabetes mellitus. 
Indien revascularisatie de voorkeur had, was CABG de voorgenomen 
behandeling bij 35% van de diabeten en bij 33% van de niet-diabeten. 
Multivariate analyses veranderden deze bevindingen niet. In bepaalde 
subgroepen werd de behandel beslissing wel beïnvloed door de 
aanwezigheid van diabetes mellitus. Bijvoorbeeld, revascularisatie had 
vaker de voorkeur bij diabeten met mild hartfalen (91%) in vergelijking met 
Samenvatting en Conclusies 
___________________________________________________________________ 
170
niet-diabeten (67%, p<0,001). Bij patiënten met ernstigere coronair 
afwijkingen (hoofdstam-stenose, meervatslijden, of proximale LAD) werden 
behandel beslissingen niet beïnvloed door de aan- of afwezigheid van 
diabetes mellitus. 
Diabetes mellitus was, onafhankelijk van de voorgenomen therapie, niet 
geassocieerd met een hogere sterfte, niet-fataal cerebro-vasculair accident 
of niet-fataal myocardinfarct na 1 jaar vervolgonderzoek. De incidentie van 
het gecombineerde eindpunt was 7,3% in diabeten en 6,8% in niet-
diabeten (na multivariate analyse hazard ratio 1,0 met 95% 
betrouwbaarheids interval 0,7 tot 1,4). 
Behandel beslissingen betreffende revascularisatie en de keus tussen 
CABG of PCI, blijken dus niet beïnvloed door de aan- of afwezigheid van 
diabetes mellitus bij patiënten met stabiele angina pectoris en diabetes 
mellitus was niet geassocieerd met een slechte prognose. 
Slotconclusies en toekomstige ontwikkelingen 
Coronaire revascularisatie met behulp van PCI of CABG is een belangrijke 
optie voor patiënten met (symptomatisch)  coronairlijden. Deze therapie 
kan symptomen verminderen en bij sommige patiënten het leven 
verlengen. Ofschoon beide revascularisatie therapieën zijn verbeterd 
gedurende de laatste decennia, blijft het een uitdaging voor de toekomst 
om de meest geschikte therapie op het juiste moment bij de individuele 
patiënt toe te passen. Gerandomiseerde studies zijn van groot belang voor 
het nemen van beslissingen. Echter, de meeste gerandomiseerde studies 
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hebben ook belangrijke beperkingen, zoals lage externe validiteit en een 
beperkte follow-up periode. Verder zijn de meeste gerandomiseerde 
studies die betrekking hebben op revascularisatie therapieën niet 
geblindeerd en kunnen resultaten worden beïnvloed door “cross-over”. 
Daarom moeten deze studies worden gecombineerd met observationele 
studies. Aangezien behandelingen en behandelstrategieën veranderen, is 
een voortdurende evaluatie van het effect van behandelingen ( van 
subgroepen) in de dagelijkse praktijk noodzakelijk. 
De uitgebreidheid van het coronairlijden speelt een belangrijke rol in de 
keus voor revascularisatie en de selectie voor CABG of PCI. Volledigheid 
van revascularisatie kan de prognose verbeteren. Of bij patiënten met 
meervatslijden, CABG of PCI  de voorkeurstherapie is, dient nog verder te 
worden uitgezocht in vele subgroepen van patiënten met coronairlijden, in 
het bijzonder bij diabetes mellitus. 
Diabetes mellitus is één van de belangrijkste risicofactoren voor 
coronairlijden. Daarnaast is er een snelle toename van de prevalentie van 
diabetes mellitus in de algemene populatie. Het is nog steeds onzeker of 
PCI dan wel CABG de voorkeursbehandeling is bij de meerderheid van 
patiënten met diabetes mellitus en coronairlijden. Vermoedelijk zullen anti-
restenotische, drug-eluting stents (DES) de resultaten van  PCI in 
vergelijking met CABG bij deze patiënten verbeteren. Toekomstige studies 
als de CARDia, FREEDOM en BARI 2D, waarin patiënten met 
coronairlijden en diabetes mellitus worden geincludeerd, en vervolgens 
gerandomiseerd naar CABG of PCI met DES en moderne anti-plaatjes 
therapie, inclusief GP IIb/IIIa inhibitors en clopidogrel, zullen waarschijnlijk 
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